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Abstract 
Cancer is the second highest cause of death in the US, and chemotherapy is one of the 
common cancer therapies. In order to reduce side effects and avoid cancer’s resistance to 
antitumor drugs, we use nanoparticle (NP)-assisted chemotherapy. This strategy can selectively 
deliver high concentrations of antitumor drugs to the tumor area, because NPs can encapsulate 
antitumor drugs, target the tumor area by active and passive targeting mechanisms, and release 
the drugs inside the cancer cells. This work focuses on three aspects of such NPs: high loading 
with antitumor drugs, controlled release of antitumor drugs, and high cellular uptake by the NPs. 
As a model system, polyacrylamide-based NPs were loaded with cisplatin. The effects of 
functional groups in the NPs, and the effects of matrix densities, were evaluated in terms of the 
NPs’ drug-loading, their release profile, and their cellular uptake. The carboxyl-functionalized 
NPs achieved 2 times higher loading and faster release of cisplatin than the amine-functionalized 
NPs. In contrast, the amine-functionalized NPs had 3.5 times better cellular uptake than the 
carboxyl-functionalized NPs. Tuning the matrix density of those NPs could control the release of 
cisplatin. Also, cisplatin-loaded, temperature-responsive NPs were synthesized so as to 
incorporate a trigger for cisplatin release in the cancer cells. The elevated temperature 
successfully enhanced the release of cisplatin from the synthesized NPs, especially under acidic 
conditions simulating lysosomes, which were the destination of the NPs inside the cells. Also, 
the in vitro cytotoxicity of the NPs is accelerated at high temperature. Finally, polyethylenimine 
(PEI) was incorporated into cisplatin-loaded PAA-NPs. Incorporation of PEI enhanced the 
xiii 
 
cellular uptake of the PAA NPs 7 times, and resulted in significantly higher cytotoxicity. Other 
properties of these NPs, such as enhanced loading, enhanced release, and endosomal escape may 
contribute to their higher cytotoxicity. These results confirmed the importance of the following 
three factors when designing NPs for NP-assisted chemotherapy: (1) high loading with antitumor 
drugs, (2) controlled release of antitumor drugs, and (3) high cellular uptake of the NPs.  
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Chapter 1 
Introduction 
 
Cancer  Statistics. 
Thanks to the recent development of early diagnosis and treatment of cancer, the growth 
in the number of death by cancer has been suppressed, based on the statistics in 2014.
 1
 However, 
cancer is still the second highest cause of death in US in recent years, and the first cause of death 
by disease for people younger than 80, except for males whose age is 20 to 39.
 1
 Therefore, 
establishing new methods of treatment of cancer is in high demand. 
 
Cancer Therapies. 
Cancer is an uncontrollable and rapid growth of cells in the body.
 2
 These cells can 
migrate from an original location to another location through the lymph system and blood stream.
 
2
 The grown tumors can disable normal body functions, and, in the severe case, cause death.
 3
 
There are various types of proposed cancer treatments: surgery, radiation therapy, 
chemotherapy, and photodynamic therapy.
 4
 All these therapies aim for the removal of cancer 
cells from the body. Surgery is the physical removal of the tumor from the body. Radiation 
therapy dysfunctions DNA in the cancer cells, and causes apoptosis by radiation, which is most 
commonly performed utilizing an external radiation source.
 5,6
 Chemotherapy attacks cancer cells 
by small molecules, targeted towards rapid growth or biomarkers that are highly expressed in the 
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tumor area.
 7,8
 Photodynamic therapy is a relatively new treatment which utilizes reactive oxygen 
species (ROS), produced by photosensitizers. The ROS oxidize various parts of the cells, and 
lead to cell death.
 4
  
Surgery, radiation therapy and chemotherapy are the most common treatment currently. 
Surgery is the most invasive method, but enables the removal of a large volume of tumor. On the 
other hand, radiation therapy and chemotherapy are less invasive and indirect treatments.
 4
 Due 
to their lesser invasiveness, these therapies are often prescribed prior to surgery, or after the 
surgery as adjuvant therapies.
 8,9
  
 
Problems with Chemotherapy. 
Even though chemotherapy is less invasive, it is known to cause severe side effects, due 
to a nontargeted distribution of drugs.
 4
 In addition, chemotherapy may not completely eradicate 
the tumor, and cancer may relapse after chemotherapy.
 10
 
One of the reasons of the relapse is due to cancer cells’ intrinsic resistance against these 
drugs, the so-called multidrug resistance (MDR).
 10
 Because of their MDR ability, some cancer 
cells may survive the chemotherapy. MDR is a combination effect of mechanisms of the tumor 
cells, to fight antitumor drugs. ATP-binding cassette (ABC) transporters play an important and 
most widely discussed role among MDR transporters.
 11
 They actively transport drugs out of the 
body. For example, ABCC2, ATP7A, and ATP7B are reported to pump out cisplatin,
 12,13
 and P-
gp, MRP1, ABCC2, and ABCG2 are reported to pump out doxorubicin.
 12,14,15
 
Another MDR mechanism is the so-called quiescent state. Some of the resistant cells are 
fundamentally arrested in a G0-G1 state.
 16
 Therefore, chemodrugs that work during the cell 
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division are not effective.
13
 Also, these cells can have an enhanced DNA repairing ability,
 17
 as 
well as adapt to a hypoxic environment.
 18
 Another mechanism of drug resistance is anti-
apoptosis. A higher expression of the anti-apoptosis genes (FLIP, BCL-2, BCL-XL,
 19
 and of the 
inhibitor of apoptosis protein (IAP) family members
20
) was observed in some of these resistant 
cells. Also, DNA damages can cause a loss of ability of proceeding to apoptosis.
 21
 In addition to 
these cellular functions, the environment in the tumor, such as high interstitial fluid pressure,
 22,23
 
hypoxia
24
 and low pH,
 25,26
 contribute to MDR as well.
 12
 Due to these MDR abilities, the 
chemotherapy of cells with MDR is challenging.  
 Solving the problem of MDR ability of cancer cells is important not simply because we 
can treat cancer more effectively, but also because cancer stem cells, which play an important 
role in relapse and metastasis, are known to have such MDR mechanisms.
 10
 Therefore, in order 
to completely eradicate the tumor, it is mandatory to overcome the problem of MDR. 
Prospective chemotherapy needs to overcome the problems described above: side effects 
and MDR, so as to improve the quality of life of the patients, as well as increasing the drug 
efficacy. A simple method to solve the problem of MDR is to increase the amount (dose) of 
antitumor drugs that are delivered to the tumor areas so that they can override the MDR of 
tumors. However, simply increasing the dose of drugs causes an increase in the risk of resulting 
severe side effects. Therefore, instead of increasing the overall dose of antitumor drugs, it is 
necessary to increase their local dose. 
 
NPs-Assisted Chemotherapy. 
1) Advantages of using NPs-Assisted Chemotherapy. 
4 
 
Nanoparticle (NP)-assisted selective delivery of antitumor drugs, a so-called drug 
delivery system, has been proposed as a promising strategy to achieve this goal, because of these 
systems’ intrinsic property to selectively accumulate in the tumor area, due to the size of these 
NPs. Chemotherapeutic agents are loaded into NPs, and NPs serve as carrier of the agent to the 
tumor area. Hiroshi Maeda found that cancerous tumors have a bigger than normal size of pores, 
in their blood vessels, so that macromolecules, like NPs, penetrate through the tumor 
vasculatures more easily than through the vasculatures of normal tissues (“leaky tumor blood 
vessels”). 27 Also, cancerous tumors can remove these macromolecules less efficiently than the 
normal tissues (poor lymphatic drainage).
 27
 As a result, polyacrylamide-based (PAA)-NPs 
selectively accumulate in the cancerous tumors, compared to the rest of the body. This 
phenomenon is called “enhanced permeability and retention” (EPR). 27  
Traditionally, the chemodrug/contrast-agent molecules needed to be chemically modified 
for improving the in vivo efficacy and pharmacokinetic behavior of the drugs. However, these 
procedures require long times and occasionally these chemical modifications can end up in an 
unexpected loss of their desirable properties. By encapsulating drugs into NPs, the drug-loaded 
NPs can gain such improvement, i.e. better in vivo efficacy and better pharmacokinetic behavior, 
without alternating the chemical or physical properties of the drugs itself. One example of NP 
advantages is the conjugation to the NPs of active targeting moieties. By conjugating targeting 
moieties such as antibody, small peptide, or aptamer, the cancerous cell-targeting ability of NPs 
can be enhanced furthermore.
 28–30
 We have previously shown that the addition of F3, a 34 amino 
acid peptide originally from the high mobility group protein 2, HMG2N,
 31
 can enable NPs to 
stay in the tumor areas for a significantly longer time than non-targeted NPs.
 32
  Another example 
is the conjugation of polyethylene glycol (PEG). It is reported that by coating the surface of the 
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NPs by PEG, the circulation time of NPs in the blood much increases, due to the avoidance of 
the interaction with blood proteins, and also due to the prevention of NPs from being engulfed by 
macrophages, and being rapidly cleared from the body.
 33,34
 The longer circulation also lets more 
NPs reach the tumor areas.  
In addition to enabling drugs to target the tumor, the NPs can protect drugs from 
degradation.
 35,36
 A common problem of small molecule drugs is their degradation by enzymes in 
the blood.
 36
 The degradation of drugs reduces the number of active drug molecules at the tumor 
areas. NPs can physically protect these drugs from degradation, by preventing these enzymes 
from interacting with drugs, by coating the drugs.
 36
 Therefore, utilizing these properties, more 
and more drug-encapsulated NPs are being developed for commercialization now. 
Doxorubicin-encapsulated liposome, the so-called Doxil, is the first U.S. Food and Drug 
Administration (FDA) approved nanoparticle-based chemotherapeutic agent.
 34
 It was approved 
by the FDA in 1995.
 34
 It is aiming for the prolonged circulation inside the body, and the 
protection of doxorubicin from degradation.
 34
 It is used for metastatic breast cancer, recurrent 
ovarian cancer, and multiple myeloma, Kaposi’s sarcoma. 34 Another example is paclitaxel-
bound albumin, called Abraxane. It is developed by Abraxis Bioscience, and approved by the 
U.S. Food and Drug Administration (FDA) in 2005. It is used for the treatment of pancreatic 
cancer, non-small cell lung cancer, and breast cancer.
 37–39
  
 
2) Types of NPs-Assisted Chemotherapy. 
Various types of materials and various methods of formation of these nanocarriers have 
been proposed. Some examples of these nanocarriers are liposomes,
 34,40,41
 polymeric micelles,
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42–44
 dendrimers,
 45,46
 polysaccharides,
 47
 and inorganic NPs.
 40,48
 Liposomes are one of the oldest 
formulations people have developed as nanocarriers.
 41
 It is the micelle whose layers are made of 
lipids.
 41
 Polymeric micelles use amphiphilic polymer chains, instead of lipids, to form micelles, 
so as to have additional functionality.
 42
 Dendrimers are branched polymer networks, which 
typically have 4-5 generations.
 45,46
 They are widely used as carriers for genes due to their ability 
to escape endosomes.
 46
 Various polysaccharides are used as a carrier of drugs.
 47,49
 One  example 
is hyaluronic acid; hyaluronic acid is used as a carrier of cisplatin due to the abundance of 
carboxylic groups in its structure.
 47
 Typical inorganic NPs used as a drug carrier are iron oxide 
and gold NPs.
 40,48
 They typically have a core of inorganic materials and a shell of organic 
materials, in order to capture drugs and increase the stability of the core material itself. Inorganic 
NPs themselves do not encapsulate drugs inside their structure, but capture drugs on their surface. 
These inorganic cores help in controlling the release of drugs.
 40,48
 
In Dr. Kopelman’s group, we utilize the hydrogel polyacrylamide (PAA) as a basic 
structure of NPs. We have shown that PAA-NPs are biocompatible both in vitro and in vivo.
 30,50
 
Also, the system has high engineerability as well. By varying the monomers and cross-linkers, 
along with acrylamide, the charge of the NPs and the hydrophobicity inside NPs’ matrix and can 
be tuned. These properties are important for controlling the retention and release of drugs inside 
the NPs. Thus, it is ideal for synthesizing highly functional hydrogel NPs for biomedical 
applications.  
PAA-NPs are composed of three different components: acrylamide, secondary monomer, 
and cross-linker. Acrylamide is the main ingredient of the NPs. Its polymer is chemically inert, 
has a neutral charge, and is highly biocompatible. The secondary monomer determines the 
overall charge of the NPs. Some of the secondary monomers we have used are: A primary 
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amine-containing monomer, 3-(aminopropyl)methacrylamide (APMA),
 30
 carboxyl-containing 
monomer, acrylic acid
50
 and 2-carboxyethyl acrylate.
 35
 APMA can be used to load negatively 
charged drugs such as RNA and DNA, and to conjugate targeting moieties such as F3, via 
bifunctional PEG, maleimide-PEG-N-hydroxylsuccinimide ester.
 51
 The amount of the secondary 
monomer is tuned to minimize the toxicity from a functional group of the secondary monomer, 
and to also tune the drug retaining and releasing ability of the NPs.
 35
 The cross-linker links the 
polymer chains inside the NP to pack the matrix and form a stable spherical shape. By 
incorporating the ester groups inside the cross-linkers, the NPs gradually degrades inside the 
body, and can be bio-eliminated from the body.
 52,53
 Also, by changing the length of the polymer 
chain, the intermolecular distance of the drug molecules inside the NPs can be tuned.
 36
 
The PAA-NPs are size tunable. It is reported that PAA-NPs can have a size ranging from 
30nm to 10μm. 54 For our purpose, we aimed at a size of PAA-NPs of less than 100 nm, so that 
these NPs can pass through the blood-brain-barrier, for the treatment of brain tumors.
 55
 In order 
to tune the size, PAA-NPs are synthesized using the reverse-micelle polymerization method.
 56
 
This system is composed of three parts; oil, water and surfactants. The oil is the continuous 
phase in our reverse micelle system. Hexane typically acts as an oil phase in our system. All NP 
ingredients are dissolved in water, which only has 1/20 to 1/40 of the volume of hexane. An 
ionic surfactant, dioctyl sulfosuccinate (AOT), and a nonionic surfactant, Brij30, are used as 
surfactants in our system;
 56
 the surfactant combination makes the microemulsion temperature 
independent.
 57
 By changing the ratio among oil, water, and surfactants, the size of the micelle 
can be tuned.
 56
 The polymerization of the NPs ingredients is started by initiators, i.e., 
ammonium persulfate (APS) and N,N,N',N'-tetramethylethylenediamine (TEMED). 
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Goals of Dissertation. 
In this work, cisplatin-loaded PAA-based NPs were developed for chemotherapy. 
Cisplatin is a good model drug for my research because it has platinum on its center.
 58
 The 
platinum makes the quantification of drugs in the NPs and in the NPs treated-cells easier than 
other organic chemotherapeutic agents, such as paclitaxel and docetaxel, which need 
quantification by UV spectroscopy or mass spectroscopy where various molecules in the cells 
and NPs can interfere.
 59–61
 Also, it is one of the earliest chemotherapeutic agents, and known to 
has severe side effects; therefore, delivering cisplatin to the tumor with lower systemic side 
effects will be a great contribution to current chemotherapy.
 62,63
 
We previously reported a treatment of ovarian cancer utilizing PAA-based NPs.
 30
 We 
aimed to eradicate ovarian cancer in a mouse model. With F3-conjugated NPs, we had success in 
suppressing the tumor volume, whereas free cisplatin did not show any effect, due to the known 
cisplatin resistance of the utilized cancer cells.
 30
 However, the NPs had a low loading of 
cisplatin, poor results in in vitro study, and no analysis on the cisplatin release behavior.
 30
 
Therefore, in my dissertation, I focused on the improvement of the promising NPs formulation. 
To improve the efficacy of the NPs, I focused on three critical factors of the NPs-assisted 
chemotherapy: (1) loading efficiency of cisplatin, (2) release profile of cisplatin, (3) cellular 
uptake efficiency. 
Loading efficiency is a critical factor for NPs-assisted chemotherapy. Even though PAA-
NPs are biocompatible, the dose of the NPs is limited. Therefore, in order to deliver an effective 
amount of drugs to the tumor, the NPs should be able to load a high amount of drugs. In fact, our 
previous work was successful in the shrinkage of the tumor, but could not completely eradicate 
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the tumor.
 30
 This could be because the dose of cisplatin was only one third of the dose of free 
cisplatin.
 30
 If the loading of cisplatin had been higher, the efficacy could have been even higher. 
The loading of cisplatin can be controlled by changing the timing of loading cisplatin, the 
loading temperature, and the secondary monomer.
 44,47
 These conditions will be discussed further 
in chapters 2 and 3. 
The controlled release of drugs is also a critical factor for NPs-assisted chemotherapy. In 
order to maximize the amount of drug delivered to the tumor area, the ideal NPs should release 
no drugs while the NPs are circulating in the blood, and release all drugs in the tumor area. 
However, in reality, the drugs are slowly leaching out from NPs even while circulating in the 
blood. Therefore, it is necessary to tune the release kinetics in a way that it does not rapidly 
release the entire drug in the blood or that the concentration of the released drug is too high, so as 
not to cause severe side effects. On the other hand, if the NPs release drugs too slowly, the 
concentration of the active drugs in the tumor area is insufficient for the treatment. Our PAA-
NPs are reported to have a plasma half-life of 35 hours.
 33
 Therefore, if the NPs can gradually 
release cisplatin over several days, instead of several hours or several weeks, such NPs can 
continuously supply effective amounts of drugs to the tumor, while reducing their side effects, 
due to targeting. 
Another method to control the release of drugs is to add a release trigger to the NPs
4
. In 
this way, the NPs can change the release kinetics drastically when the NPs migrate from the 
blood vessel to the tumor area. Some examples of triggers are light,
 64,65
 pH,
 66
 temperature,
 50,66
 
antigen,
 67
 glucose,
 68
 and a reducing environment.
 69
 By adding such a trigger, the delivery of 
drugs to the tumor areas will be more effective. An example of a thermally controlled release of 
drugs from NPs will be discussed in chapter 3. 
10 
 
Cellular uptake efficiency is also a critical factor for these NPs. The closer the drugs are 
released to the site of action, the more effective the treatment is. For example, cisplatin chelates 
DNA in nucleus. The closer cisplatin in NPs is released to the nucleus, the better the therapeutic 
effect is.
 70
 Therefore, the efficacy will be higher if the drugs are released from the NPs after the 
NPs are inside the cells than if the drugs are released before entering the cells. Also, it is reported 
that NPs can avoid MDR pumps.
 71,72
 The avoidance of MDR is possibly because free drug 
molecules diffuse through cell membrane, and these pumps work mainly when drug molecules 
are penetrating through the membrane; however, this remains under discussion.
 73
 Thus, if we 
could release drugs after the NPs are taken up by the cells, we could avoid the efflux of drugs, 
which can further enhance the therapeutic effect.  
The surface properties, such as charge, of the NPs are an important factor influencing 
cellular uptake efficiency.  The higher the positive charge, the higher the cellular uptake, because 
the cell membrane is negatively charged.
 74
 Also, the lower the negative charge, the better the 
cellular uptake is.
 74
 Also, it is reported that pathways NPs take to be uptaken by the cells are 
different between positively charged NPs and negatively charged NPs, due to the difference in 
the interaction with blood plasma proteins such as albumin.
 75
 Positively charged NPs deform the 
structure of the proteins on the surface of the NPs; therefore, they are uptaken by the scavenger 
receptor.
 75
 On the other hand, negatively charged NPs do not deform the structure of the proteins 
on the surface of the NPs; therefore they are uptaken via protein receptors, such as the albumin 
receptor.
 75
 The relationship between the NPs’ surface and the cellular uptake is further discussed 
in chapter 5. 
Another approach to increase the cellular uptake is to add some targeting moieties on the 
surface of the NPs, so as to increase the chance of receptor mediated endocytosis. Some of the 
11 
 
commonly used targeting moieties are anti-VEGF, folic acid, and F3 peptide. We have 
previously shown that cells that are expressing high amounts of nucleolin on the membrane 
surface can uptake more F3-conjugated NPs than non-conjugated NPs.
 51,76
  
In order to analyze these factors, we utilize various analytical methods. The size and 
surface charge of NPs is measured using dynamic light scattering (DLS)
 77
 and electrophoretic 
light scattering,
 78
 where the instrument can measure the hydrodynamic size, size distribution, 
and the zeta-potential of the NPs, respectively. Also, transmittance electron microscopy and 
scanning electron microscopy can be utilized to measure the NPs in the dried state, and evaluate 
the size uniformity of the NPs. The cisplatin loading content, the amount of cisplatin in the cells, 
and the cisplatin release from the NPs can all be quantified by using inductively coupled plasma 
optical emission spectroscopy (ICP-OES). Fluorescence microscopy, especially confocal 
microscopy, can be utilized to evaluate the location of the NPs in the cells, as well as the amount 
of NPs uptaken by the cells. Flow cytometry can be utilized as well to measure the amount of 
NPs uptaken by the cells. 
 
Structure of the Dissertation. 
The structure of my dissertation is the following. 
Chapter 2. 
A nanoparticle (NP)-based antitumor drug carrier has been an emerging strategy for 
selectively delivering the drugs to the tumor area and, thus, reducing side effects that are 
associated with a high systemic dose of antitumor drugs. Precise control of the drug release from 
these NPs is critical so as to maximize the NPs’ therapeutic index. Here, we propose a simple 
12 
 
method of synthesizing NPs with tunable drug release while maintaining their loading ability: 
changing the matrix density of amine-functionalized hydrogel NPs as well as of carboxyl-
functionalized hydrogel NPs. The NPs with looser matrix released more cisplatin and at a faster 
rate. Carboxyl-functionalized NPs loaded more cisplatin and released at faster rate than amine-
functionalized NPs. Also, we compared cellular uptake between amine-functionalized NPs and 
carboxyl-functionalized NPs: The amine-functionalized NPs can deliver 3.5 times more cisplatin 
into cells than the carboxyl-functionalized NPs. Both the consideration of controlled release and 
uptake is required for designing potent drug-loaded NPs. Also, we discussed their cytotoxicity. 
Shirakura, T., Smith, C. Koo Lee, Y.-E., and Kopelman R. “Hydrogel Nanoparticle Matrix 
Density and Surface Charge Engineering: Tuning Chemodrug Loading, Release, and Cellular 
Uptake.” In preparation. 
 
Chapter 3. 
One of the properties that drug-loaded NPs need to have is control of the drug release. 
Ideally, the drugs are released only at the tumor areas. I incorporated a useful temperature-
sensitivity into my NPs. Unlike typical temperature-sensitive NPs, which squeeze out the drugs 
at the elevated temperature, my NPs swell with temperature, which enhance their drug release at 
the tumors’ elevated temperature.  I confirmed the temperature-sensitivity of cisplatin release at 
the physiological pH of 7.4 and also at pH 4, which is close to the lysosomal pH of 4.5, where 
these NPs were trapped inside the cells. Also, we observed enhanced cytotoxicity of cisplatin-
loaded NPs at elevated temperatures in vitro; even though free cisplatin is less effective at these 
elevated temperatures. These finding expanded the choice of possible formulations of the 
13 
 
development of improved drug delivery systems, by demonstrating this new alternative choice of 
a temperature sensitive material. 
Shirakura, T.; Kelson, T.; Ray, A.; Malyarenko, A.; Kopelman, R. “Hydrogel Nanoparticles 
with Thermally Controlled Drug Release.” ACS Macro Letters 2014, 3, 602606. 
 
Chapter 4. 
The efficacy of drug-loaded NPs is directly related to the cellular uptake of NPs. The 
higher the cellular uptake, the better the efficacy. Therefore, I embedded PEI into our cisplatin-
loaded NPs, and compared them with cisplatin-loaded PAA NPs without PEI, in terms of their 
cellular uptake and cytotoxicity. I found that the cellular uptake was significantly enhanced by 
PEI, even though there was no enhancement of surface potential (ζ-potential) between the PEI-
incorporated NPs and the NPs without PEI. Also, due to their higher cellular uptake, the PEI-
embedded NPs had higher cytotoxicity than the NPs without PEI when loaded with cisplatin. 
Also, PEI-incorporated NPs showed marginal increase of loading, faster release kinetics, and 
ability of endosomal escape. High cellular uptake and these factors contribute to the higher 
cytotoxicity of cisplatin-loaded PEI-incorporated PAA NPs than PAA NPs. The finding 
emphasizes the importance of the cellular uptake of NPs for the efficacy of NPs-based 
chemotherapy, and suggests a new method for enhancing the cellular uptake. 
Shirakura, T. Ray, A. Kopelman R. “Polyethylenimine-Incorporation into Hydrogel 
Nanoparticles for Enhanced Chemotherapy.” In preparation. 
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Chapter 2. 
Hydrogel Nanoparticle Matrix Density and Surface Charge Engineering: Tuning 
Chemodrug Loading, Release, and Cellular Uptake 
 
The material in this chapter has been adapted with minor modifications from the following 
prospective publication. 
Shirakura, T., Smith, C. Koo Lee, Y.-E., and Kopelman R. “Hydrogel Nanoparticle Matrix 
Density and Surface Charge Engineering: Tuning Chemodrug Loading, Release, and Cellular 
Uptake.” In preparation. 
  
 
Introduction 
Cancer is the second highest cause of mortality in recent years in the US.
1
 The main 
cancer treatments include surgery, radiation therapy, chemotherapy and their combinations. 
Chemotherapy of cancer is a non-invasive and powerful treatment, and cisplatin is one of the 
most widely used chemodrugs, which has been used to treat breast, ovarian, bladder, lung, and 
head and neck cancers.
2,3
 On the other hand, it is also known that many types of cancer show 
resistance to cisplatin because of the cells’ high expression of drug-efflux pumps, enhanced DNA 
repair mechanisms, avoidance of apoptosis, or high concentration of reducing agents or chloride 
ions, all together called multi-drug resistance (MDR).
4–7
 An increase in the dose of cisplatin is 
helpful to override MDR. However, administering a globally high dose of cisplatin is likely to 
20 
 
cause serious side effects, due to its high reactivity to any types of rapidly dividing cells.
8
 
Therefore, a targeted delivery of cisplatin to cancer tumor is necessary so as to override MDR 
with an enhanced local dose, and, at the same time, to avoid an increased global dose that would 
results in side effects. 
A targeted delivery of cisplatin to cancerous tumors via nanoparticles (NPs) can 
potentially achieve the required locally high dose of cisplatin in the tumors. The targeting ability 
of NPs to the tumor area depends on two different types of targeting mechanisms: active 
targeting and passive targeting. Active targeting utilizes antibody,
9
 aptamer,
3
 or peptide
10
 
conjugated NPs, so as to aim at receptors or biomarker that are highly expressed on the surface 
of cancer cells. On the other hand, passive targeting relies on the accumulation of 
macromolecules such as NPs in the tumors due to the so called “enhanced permeability and 
retention (EPR)” effect.11,12  
Furthermore, the NP-based delivery can inherently avoid MDR, as NPs are taken up in 
the cells’ endocytotic vesicles, and therefore, they and their contents are not immediately 
accessible to the efflux pumps located in the cellular membrane, unlike molecular drugs that 
diffuse in through the cell membrane.
13–16
 Also, the large number of drug molecules released by 
one NP may overload the cell’s efflux capacity. 
Many groups have developed various types of nanoplatforms for cisplatin delivery, such 
as PLGA,
3
 hyaluronic acid,
17
 lipid
8,18,19
 or block copolymer.
20,21
 Our group has made various 
types of polyacrylamide-based NPs (PAA-NPs) for cancer diagnosis
13,22–24
 and therapy,
10,25,26
 due 
to its ideal characteristics as a platform drug delivery system. PAA-NPs have proven to be 
biocompatible both in vitro and in vivo.
10,27
 In addition, the hydrophilicity and the surface charge 
of the NPs can be easy manipulated by changing the type and relative ratio of acrylamide 
21 
 
derivative monomers in the synthesis.
28
 This high engineerability also allows for the conjugation 
of many different types of cancer-targeting moieties onto the surface of PAA-NPs for the active 
targeting.
10,29
 We previously showed that cisplatin-loaded hydrogel NPs could target SKOV3 
ovarian cancer and successfully shrink the tumor size, while free cisplatin had no effect at all on 
the tumor growth due to this tumors’ known cisplatin resistance.10 
Kinetically controlled release of the drugs is important for optimal drug delivery so that 
the NPs do not release drugs while still circulating in the blood-stream but release most of the 
drugs when reaching at the tumor area. Such temporally and spatially controlled release behavior 
can avoid, or at least reduce, the side effects that are associated with globally high doses of 
cisplatin.
29
 
The drug release behavior of hydrogel can be tuned by changing its mesh size, porosity, 
tortuosity, and hydration rate.
30,31
 In NP-based drug delivery systems, the mesh size plays an 
important role.
29,32,33
 The mesh size is defined by the distance between two polymeric chain 
cross-linkers, which can be defined by equation 1.
32
 
 = 𝑄
1
3 [𝐶𝑛
2𝑀𝐶̅̅ ̅̅̅
𝑀𝑟
]
1
2
        Equation (1) 
Here, Q is the swell ratio of the matrix, Cn is the Flory characteristic ratio of the hydrogel, which 
describes the flexibility of the chain,
34
 Mc is the average molecular weight of a chain between 
cross-linkers, and Mr is the molecular weight of a repeating unit. NPs with bigger mesh size 
release the drugs faster.
33
  
The cross-linkers can be classified in two types: chemical and physical. In the typical 
hydrogel NPs, they coexist.
31
 Chemical cross-linkers, such as tetraethylene glycol 
dimethacrylate,
32
 or poly(ethylene glycol) dimethacrylate,
35
 form rigid connections between 
polymer chains by forming covalent bonding. On the other hand, physical cross-linkers form 
22 
 
weak and reversible connections.
31
 Some examples are hydrogen bonding, ionic bonding and 
crystallite formations. 
31
  
One approach to change the mesh size (i.e. tune the drug-release kinetics) is varying the 
relative ratio of chemical cross-linker in the hydrogel (i.e. change Mc in Equation 1).
32,35
 This 
approach changes the distance between cross-linkers permanently, by varying the number of 
chemical cross-linkers.  
Another approach is to make physical cross-linkers sensitive to the surrounding 
environment, such as pH and temperature.
36–38
 By forming hydrogen bonding, by incorporating 
charged or polar components in the matrix, the hydrogen bonding can be broken upon change in 
environment.
38
 This approach changes the distance between cross-linkers temporarily and 
reversibly, by varying the number of physical cross-linkers.  
As an example of controlling drug release from NPs by environment-sensitive physical 
cross-linking, we previously reported poly(acrylamide-co-acrylic acid) hydrogels as carriers of 
cisplatin.
37 
These NPs have a temperature-sensitive property, and swell as the temperature of the 
matrix increases, by cutting the physical cross-linking due to hydrogen bonding. This reduces the 
NPs’ matrix density. The matrix density is directly related to the mesh size, because a denser 
matrix can form more physical cross-linking inside. Thus, the reduction of the matrix density 
increases the mesh size, and enhances the release of cisplatin from the NPs.
33
  
However, these environment-responsive NPs turn on/off the drug release typically due to 
a combination of various factors. For example, in our system (will be further discussed in chapter 
2), the enhancement of the release at higher temperature was a combination effect, including the 
expansion of the matrix volume (i.e. decline of the matrix density), faster diffusion of drugs and 
ions, and an enhanced kinetics of a chemical reaction of detaching cisplatin from the matrix. 
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Therefore, in order to further understand just the effect of the matrix density on the release 
profile, it is necessary to develop NPs where the release depends only on the NP matrix density.  
Here, we synthesized distinct PAA-NPs that had a similar size, but different matrix 
density, and compared their release profile. The synthesis was done by using the property of the 
reverse micelle polymerization method, where the size of the synthesized NPs depends on the 
formed micelle size, but is little affected by the NP ingredients within the range of concentration 
of NPs forming ingredients we utilized.
10,39
 This enables the synthesis of NPs that have similar 
degrees of chemical cross-linking, but different degrees of physical cross-linking, due to an 
increase of the empty space in the matrix. This can 1) mimic the situation of the swollen state of 
environment-responsive NPs, which would change the degree of physical cross-linking while 
maintaining the chemical cross-linking; 2) change the mesh size more drastically than the 
method of adjusting the ratio of the chemical cross-linkers.  
Utilizing this system, we evaluated the effect of changing the matrix density of the NPs, 
so as to tune the release profile of cisplatin from two commonly used PAA NPs: amine-
functionalized and carboxyl-functionalized.
10,28,37
 Carboxyl-functionalized NPs loaded with more 
cisplatin and released more cisplatin, in a given time, than amine-functionalized NPs. More 
importantly, the synthesized NPs showed the similar cisplatin loading capacities regardless of the 
matrix density, but the kinetics of their cisplatin release showed an inverse relationship with their 
matrix density in both types of NPs. In other words, we successfully changed the release profile 
of cisplatin from the NPs while maintaining their drug-loading ability. Also, we evaluated the 
effect of the surface charge and chemistry of NPs on their cellular uptake, the latter being another 
important aspect of NPs’ cytotoxicity, which we investigated on a cisplatin-resistant cell line, 
SKOV3.
10
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Materials and Methods. 
 
Materials. 
Cisplatin was purchased from Selleck Chemical LLC. RPMI media was purchased from 
Invitrogen. All other chemicals were purchased from Sigma-Aldrich. The de-ionized water used 
in this experiment was purified prior to the experiment, using a Milli-Q system from Millipore. 
 
Preparation of Blank Poly(acrylamide-co-N-(3-aminopropyl)methacrylamide) NPs. 
P(AAm-co-APMA) NPs were synthesized reverse micelle polymerization technique 
modifying the method described by Winer
10
. Briefly, 1.6 g of dioctyl sulfosuccinate (AOT) and 
3.47 mL of Brij30 were added to 45 mL of argon-purged hexane, and continued to be stirred and 
purged with argon for 20 minutes in a round bottom flask. The mixture of acrylamide (AAm), N-
(3-aminopropyl)methacrylamide hydrochloride (APMA), and 3-(acryloyoxy)-2-
hydroxypropylmethacrylate (AHM) in 1.3 mL of water were added to the flask, and stirred and 
purged for additional 20 minutes. The polymerization was initiated by adding 100 μL of 
10(w/v)% ammonium persulfate (APS) and N,N,N',N'-tetramethylethylenediamine (TEMED). 
After 2 hours, the polymerization was terminated by introducing the atmospheric oxygen. 
Hexane was removed by rotary evaporation. The remaining products were washed, in an Amicon 
stirred cell (Millipore), 5 times with 150 mL of ethanol and 5 times with 150 mL of water using 
300 kDa MW cut-off membrane. The obtained solution was filtered through 0.2 μm pore size 
filter, and was lyophilized for 72 hours for the long term storage.  
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Preparation of Blank Poly(acrylamide-co-acrylic acid) NPs. 
p(AAm-co-AA) NPs were synthesized in the same method as p(AAm-co-APMA) NPs 
with slight modifications. 4.8 g of dioctyl sulfosuccinate and 9.5 mL Brij30 were added to 120 
mL of argon-purged hexane, and continued to be stirred and purged with argon for 40 minutes. 
The polymerization was initiated by adding 100 μL of 50(w/v)% APS and TEMED. After 4 
hours, the polymerization was terminated by introducing the atmospheric oxygen. Hexane was 
removed by rotary evaporation. The remaining products were washed in an Amicon stirred cell 
(Millipore) 7 times with 150 mL of ethanol and 5 times with 150 mL of water using 300 kDa 
MW cut-off membrane. The obtained solution was filtered through 0.2 μm pore size filter, and 
was lyophilized for 72 hours for the long term storage. 
 
Loading of Cisplatin into Blank NPs. 
10 mg of NPs were mixed with 2 mg of cisplatin dissolved in 1 mL of water. For the 
loading to p(AAm-co-APMA) NPs, 25 mM NaOH was also added to enhance the reaction 
between the carboxyl group in the NPs and cisplatin. In case of the room temperature loading, 
the mixture was kept for 3 days at the room temperature. Then, unbound cisplatin was removed 
by washing the NPs 7 times with 7 mL of water using 100 kDa MW cut-off centrifugal 
membrane (Millipore). In case of the high temperature loading, the mixture was kept in 90 °C oil 
bath for 4 hours. Then, unbound cisplatin was removed in the same procedure as the NPs 
preparation in case of the room temperature loading. The amounts of cisplatin loaded onto NPs 
were quantified using inductively coupled plasma – optical emission spectroscopy (ICP-OES). 
 
Size and Zeta-potential Measurement. 
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Dynamic light scattering was applied to measure the hydrodynamic size and the zeta-
potential of NPs using a Delsa Nano C (Beckman Coulter). The size of NPs was measured in 
PBS (pH 7.4), while the zeta-potential of NPs was measured in water. 
 
Cisplatin Release Study. 
The amount of cisplatin released from the NPs over 72 h was evaluated in phosphate 
buffer saline (PBS) (pH 7.4). NPs suspensions in PBS were prepared in the way that the 
concentration of cisplatin was 25 μg/mL. 6 of 1.5 mL Ependorf tubes were prepared, and 1 mL 
of the NPs suspension was transferred to the tubes. The tubes were kept at 37 °C until a specific 
time points: 0 hours, 6 hours, 12 hours, 24 hours and 48 hours. At the specific time points, one 
tube was filtered using 100 kDa MW cut-off centrifugal membrane, and collected the filtrate. 
The cisplatin concentration in the filtrates were quantified using ICP-OES. 
 
Cellular Cisplatin Uptake Assay. 
SKOV3 cells were cultivated in a 100 x 20 mm Petri dish to over 80 % confluency. 700 
L of cisplatin-loaded NPs were prepared in PBS with a cisplatin concentration of 25 g mL-1, 
and mixed with cells in a Petri dish containing 5 mL of complete RPMI. The cells were 
incubated with NPs for 12 hours, and harvested after that. The populations on the Petri dishes 
were counted, and the Pt content in the cells was measured using ICP-OES. The Pt content per 
cell was calculated. 
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Results and Discussion. 
 
 
Scheme 2.1. Synthesis Scheme of p(AAm-co-APMA). A) Hydrogel forming ingredients are 
trapped inside the water droplets surrounded by micelles in the hexane bath. After the 
polymerization, NPs, with the size of the micelles are formed. B) Hydrogel forming ingredients 
are acrylamide (AAm), APMA, and AHM. 
 
The cisplatin-loaded NPs were prepared in two steps: 1) synthesis of the blank NPs and 
2) post-loading of cisplatin into the blank NPs. This method enabled high loading of cisplatin, 
because blank NPs can be mixed with high concentrations of cisplatin, which otherwise would 
disrupt the microemulsion system (used in our previous synthesis had cisplatin been pre-loaded 
10
).  
 
Temperature Dependency of Cisplatin Loading. 
As a first step, in order to efficiently load cisplatin into the NPs, we investigated the 
relationship between the loading temperature and the wt% loading of cisplatin. We compared the 
loading of cisplatin at two different temperatures, utilizing the blank p(AAm-co-APMA) NPs. 
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High temperature is known to help improve the loading efficiency and also prevents the potential 
aggregation of NPs during the loading.
17
 When cisplatin was loaded at room temperature (22 °C), 
the loading of cisplatin was 0.58%, while when cisplatin was loaded into NPs at high 
temperature (90 °C), the loading was 5.63%. Thus, almost 10 times higher loading of cisplatin 
was achieved at the elevated loading temperature. The higher the temperature, the more flexible 
the NPs matrix becomes, thus the cisplatin molecules can migrate further inside the hydrogel 
NPs.
37
 Because of this high loading, we chose 90 °C as the loading temperature for the rest of the 
experiments. 
 
Synthesis of PAA-NPs of Different Matrix Density. 
In order to adjust the matrix density, NPs were synthesized with the so-called reverse 
micelle (w/o) emulsion method (Scheme 2.1A). In our system, the nano-sized water droplets, 
which contained monomers and cross-linkers, were coated by surfactants in the hexane. The free 
radical polymerization was performed, so as to form NPs inside the water droplets. The size of 
the water droplets is the critical factor for tuning the size of the synthesized NPs. One advantage 
of using this synthesis system was its ease in keeping the size of NPs constant, while changing 
the matrix density of the NPs. The matrix density was adjusted by changing the concentration of 
NP forming ingredients in the water phase, while keeping the solvent amount of the water phase 
fixed. We assume that the percent production yield of the NPs should be similar regardless of the 
concentration change. Using this method, we synthesized NPs that have different matrix 
densities as well as different compositions. 
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Table 2.1. Summary of NPs Formulations. A) NPs’ composition in different categories of NPs; 
B) Varying densities for each distinct formulation of NPs. Abbreviations: AAm, acrylamide; AA, 
acrylic acid;  APMA, N-(3-aminopropyl)methacrylamide; AHM, 3-(acryloyoxy)-2-
hydroxypropylmethacrylate. 
 
A. NPs Composition. 
p(AAm-co-APMA) mol % p(AAm-co-AA) #1 mol % p (AAm-co-AA) #2 mol % 
AAm 81.3 AAm 81.3 AAm 71.5 
APMA 2.5 AA 2.5 AA 15.2 
AHM 16.2 AHM 16.2 AHM 13.3 
 
 
B. NPs Matrix Density 
p(AAm-co-APMA) p(AAm-co-AA) #1 p(AAm-co-AA) # 2 
8.4% 16% 4.9% 
31% 25% 21 % 
48% 40% 34% 
 
The NPs formulations and their matrix densities are summarized in Table 2.1. The NP matrix 
density is estimated by the following equation (Equation 2).  
ρ =  
𝐴
𝐴+𝐵
× 100 (%),                                                                                    Equation 2. 
Here,  is the matrix density, A is the weight of hydrogel forming ingredients, and B is the 
weight of aqueous solvent during the synthesis. 
 
 
Loading of Cisplatin to AHM-APMA-AAm of Different Matrix Density. 
First, p(AAm-co-APMA) NPs of different matrix density were synthesized (Scheme 
2.1B) and were loaded with cisplatin. The result of the loading is summarized in Table 2.2. 
Interestingly, the wt% loading of cisplatin did not change with NPs of different polymer densities. 
The size of the NPs shrunk after the loading with cisplatin, possibly because cisplatin acts as a 
cross-linker, and also retracts polymer chains physically.
31
 The sizes of the cisplatin-loaded NPs 
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of different matrix densities were similar, as is expected because the sizes of the micelles during 
the synthesis were similar. No change of -potential was observed after the loading of cisplatin. 
 
Table 2.2. Cisplatin loading to the p(AHM-APMA-AAm) NPs with different matrix density. The 
densities of NPs are defined by percentage, using equation 2. 
  Blank   cisplatin-loaded wt % 
loading 
    size (nm) PDI 
ζ-potential 
(mV)   size (nm) PDI 
ζ-potential 
(mV) 
8.4 % NPs 40 (±0) 0.25 (±0.01) 10.3(± 1.6)   41 (±5) 0.27 (±0.02) 15.1(± 1) 4.7(± 0.5) 
31 % NPs 47 (±3) 0.23 (±0.06) 18.1(± 0.9)   37 (±1) 0.19 (±0.03) 18.7(± 4.1) 5.9(± 0.8) 
48 % NPs 63 (±1) 0.16 (±0.04) 30.5(± 1.9)   55 (±9) 0.17 (±0.07) 35.9(± 6.5) 5.2(± 0.7) 
 
 
Release Profile of Cisplatin Loaded p(AAm-co-APMA) NPs. 
The release profile of cisplatin from p(AAm-co-APMA) NPs of different matrix densities 
was investigated (Figure 2.1). The cisplatin-loaded 8.4 % NPs had significantly higher percent 
release of cisplatin than cisplatin-loaded 31 % and cisplatin-loaded 48 %, which should result 
from the looser matrix structure. However, we did not observe a significant difference in the % 
release of cisplatin between 48 % NPs and 31 % NPs. The change of the matrix density may not 
be significant enough to observe a notable change in the release profile. 
 
 
Figure 2.1. Cisplatin Release from cisplatin-loaded p(AAm-co-APMA) NPs over Time. The 
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release study was performed in PBS. The error bars represents the standard deviations of the 
measurement. 
 
Also, Equation 3 was applied to fit each of the release curves, so as to calculate the 
effective diffusion coefficient (D). The fit data are shown in Figure 2.2. Note that before fitting 
the equation, each data set was normalized, by subtracting from the released cisplatin at different 
time points the release amount at time 0. 
𝑀𝑡
𝑀∞
= 1 −
6
𝜋
∑
1
𝑛2
𝑒𝑥𝑝 [
−𝐷𝑛2𝜋2𝑡
𝑎2
]∞𝑛=1 + 𝐶                                                              Equation (3)
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Here, 
𝑀𝑡
𝑀∞
 represents the release ratio at time t, D is the effective diffusion coefficient of the 
cisplatin, a is the radius of the NPs and C is the fraction of cisplatin that is released during the 
initial burst release. 
 
 
Figure 2.2. Fitted Data of Cisplatin Release from p(AAm-co-APMA). The dots represent the 
experimental data, while the lines represent the fitted curve using equation 3. Note that the 
absolute release pattern is similar to the % release pattern, within error, due to the similar 
loadings of the 3 NP categories, i.e., the 8.4% NPs give the highest release, by far. 
 
The calculated Ds are summarized in Table 2.3. The 8.4 % NPs had the highest D. This is 
attributed to the lowest density of 8.4 % NPs. On the other hand, 31 % NPs had lower diffusion 
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coefficient than 48 % NPs. This contradicts the design expectations. However, the difference 
could be within the error range (see the low R
2
 value for the 24 % NPs). 
 
Table 2.3. The effective diffusion coefficient of NPs of different densities.  
NPs Density (%)   D (10-23 m2 s-1)                      R2 
8.4 0.11 0.96 
31 3.3x10-03 0.77 
48 1.7x10-02 0.91 
 
We can conclude that the AHM-APMA-AAm NPs’ cisplatin release could be tuned by 
changing the NP matrix density. 
 
 
Construction of AHM-AA-AAm NPs. 
As a next step, we evaluated the effect of the change of monomers mixed with 
acrylamide to further improve the loading and release of cisplatin (Scheme 2.2A). It has been 
reported that cisplatin chemically binds to the carboxyl groups in the absence of the Cl
-1
 ion 
(Scheme 2B).
41
 In the presence of Cl
-1
, such as in the body, or hydronium ions, such as inside 
cellular lysosomes, the carboxyl group binding to the platinum center of the cisplatin is 
substituted back by Cl
-
 or replaced with H
+
, which results in the release of cisplatin from the NPs. 
Utilizing this chemical conjugation, the loading of cisplatin can be further increased.
37
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Scheme 2.2. Synthesis Scheme of p(AAm-co-AA). A) NPs forming ingredients are acrylamide, 
acrylic acid (AA), and AHM. B) Cisplatin chemically and reversibly binds to the NPs via the 
carboxyl groups on the NPs.  
 
Table 2.4. Cisplatin loading into p(AHM-AA-AAm) NPs at different matrix densities. The 
densities of NPs are defined by percentage using equation 2. 
  blank     cisplatin-loaded  wt % 
loading 
    size (nm) PDI 
ζ-potential 
(mV)   size (nm) PDI 
ζ-potential 
(mV) 
4.9 % NPs 135 (± 5) 0.28 (± 0.03) -39.9(± 2.7)   98 ( ±2)  0.26 ( ±0.08) -44.8(± 2) 11.4(± 0.2) 
21 % NPs 39 (± 1) 0.26 (± 0.03) -35.8(± 1.9)   39 ( ±2)  0.39 ( ±0.14) -51(± 5.3) 9.9(± 0.9) 
34 % NPs 36 (± 1) 0.16 (± 0.01) -45.6(± 5.7)   43 ( ±3)  0.24 ( ±0.06) -46(± 1.6) 10.3(± 2.1) 
 
First, we constructed NPs by substituting APMA with AA without changing the molar 
ratio of the composing ingredients (p(AAm-co-AA) #1 of Table 2.1B). Into these NPs, cisplatin 
could not be loaded either at room temperature or at high temperature. These NPs formed 
aggregates during the loading procedure, possibly due to the loss of surface charge, presumably 
because of too much consumption of carboxylic groups by cisplatin. Therefore, the molar 
percentage of acrylic acid was increased (2.5% to 15%) so as to increase the stability. Also, in 
this new category of NPs, we slightly reduced the amount of cross-linkers from 16 % to 13 % 
(p(AAm-co-AA) #2 of Table 2.1B). With this new ratio of the ingredients, we attempted to load 
cisplatin into these NPs.  
When cisplatin was loaded to the above NPs at high temperature, no aggregation was 
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observed, whereas for the loading at room temperature, aggregation of the NPs was still observed. 
Also, it is reported that cisplatin can be more easily loaded into carboxyl group containing NPs 
under basic conditions; therefore, cisplatin was loaded into NPs in the presence of 25 mM 
NaOH.
36,42
 The result of the loading is summarized in Table 2.4. The sizes of the NPs were 
measured after loading with cisplatin. The 21 % NPs and 34 % NPs showed relatively similar NP 
sizes (Table 2.4). On the other hand, the 4.9 % NPs had considerably larger sizes than the other 
two NPs categories. This could be because of the swelling of the NPs due to the low cross-
linking of their matrix, as well as their high negative charge in the aqueous solvent, where there 
is no surfactant to restrict their size. Because the 4.9 % NPs were 4 times bigger size than the 
other NPs (Table 2.4), the density of 4.9 % is expected to be 8 times lower than the theoretical 
density. 
As a next step, the cisplatin release profiles of the 21 % NPs and 34 % NPs were 
evaluated (Figure 2.3).  
 
Figure 2.3. Cisplatin Release from cisplatin-loaded p(AAm-co-AA) NPs over Time. The error 
bars represent the standard deviation of the mean. 
 
As we observed in the case of the AHM-APMA-AAm NPs, 21 % NPs released more 
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cisplatin than the 34%. However, the 21 % NPs had an initial burst release of cisplatin, possibly 
due to its loose matrix. This could be due to the much larger size of the NPs, which can 
significantly slow down the release kinetics of the NPs (Equation 3).  
The effective diffusion coefficients (D) of the NPs were calculated, using Equation 3, so 
as to understand the relationship between the matrix density of the NPs and its effective diffusion 
coefficient. In order to calculate the effective diffusion coefficient, the released cisplatin at each 
time point was subtracted by the percent of cisplatin released during the initial burst. 
 
Figure 2.4. Fitted Data of Cisplatin Release from poly(AAm-co-AA). The dots represent the 
experimental data, while the lines represent the fitted curves, using equation 3. The experimental 
data up to 24 h was used to fit the data. 
  
 
Table 2.5. The effective cisplatin diffusion coefficients for NPs of different densities. 
NPs Density (%) D (10-23 m2 s-1) R2 Size (nm)  
4.9 0.63 0.96 98 ( ±2)  
21 0.39 0.94 39 ( ±2)  
34 0.25 0.99 43 ( ±3)  
 
 
The 34 % NPs had a smaller effective diffusion coefficient than the 34 % NPs, which is 
consistent with our intended design of the NPs and their release profile data (Figure 2.3). Also, 
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we calculated D for 4.9 % NPs as well. Even though the 21 % NPs showed the fastest release 
kinetics, the 4.9 % NPs had a higher effective diffusion coefficient. This is due to the size 
difference between 4.9 % NPs and 21 % NPs; the 4.9 % NPs are 2.5 times bigger than the 21 % 
NPs, on average (Table 2.5). The larger size of an NP slows down the release kinetics from the 
NP, because cisplatin molecules need to migrate over a longer distance inside the NP (Equation 
3). 
 
Comparison of Cellular Uptake between Amine-functionalized NPs and Carboxyl-
functionalized NPs. 
Cellular uptake is another important aspect of designing a highly effective drug delivery 
system, because releasing drugs inside the cells means that drugs are released closer to the site of 
action as well as that the NPs may overcome the MDR of cancer cells.
14,43
 We evaluated how the 
difference in the surface of NPs affects the cellular uptake. The cellular uptake of cisplatin was 
compared between cisplatin-loaded 31 % p(AAm-co-APMA) NPs and cisplatin-loaded 21 % 
p(AAm-co-AA) NPs, where the percentages refer to the matrix density defined by Equation 2 
(Figure 2.5). 
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Figure 2.5. Cellular Uptake Study of Cisplatin from Positively Charged NPs and Negatively 
Charged NPs. The data is normalized to the cellular uptake of p(AAm-co-AA). The 31 % 
p(AAm-co-APMA) NPs and 21 % p(AAm-co-AA) NPs were picked for the experiment; the 
percentages refer to the matrix density. 
 
There is an almost 3.5 times higher uptake of cisplatin when p(AAm-co-APMA) NPs 
were used as drug carriers than when p(AAm-co-AA) NPs were used. This higher cellular uptake 
of p(AAm-co-APMA) NPs is probably due to the preferable interaction of amine-functionalized 
NPs with cellular membranes, by electrostatic interactions, as well as by the enhancement by 
albumin.
44,45
  
 
Summary and Conclusion. 
Understanding the behavior of Drug-loaded NPs, such as drug release and cellular uptake, 
in tumor area is important for the development of highly potent NPs; especially, controlling the 
release profile of cisplatin from hydrogel NPs by tuning their matrix density was out interest. We 
used a simple method of changing the matrix density, utilizing the nature of the NPs synthesis by 
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employing reverse micelle polymerization. Two different formulations, p(AAm-co-APMA) NPs 
and p(AAm-co-AA) NPs, were tested for their release profile and cellular uptake, as function of 
their matrix density defined by equation 2. Both formulations showed an inverse relationship 
between their matrix density and their effective cisplatin diffusion coefficient, which has positive 
correlation with the mesh size of the NPs’ matrix, which is one of the critical factors determining 
the release kinetics of the NPs. P(AAm-co-AA) NPs had a better loading of cisplatin, as well as a 
faster and higher release of cisplatin than p(AAm-co-APMA) NPs. The P(AAm-co-APMA) NPs 
showed higher cellular uptake than the p(AAm-co-APMA) NPs, presumably due to their amine-
functionalization, which can facilitate the cellular uptake, via an electrostatic interaction with cell 
membranes, and assisted by albumin.
44,45
 
 
 Precise control of drug release, which can be achieved 
by changing the NPs’ matrix density, as well as the high cellular uptake, should enhance the 
efficacy of NP-assisted chemotherapy. We will evaluate the cytotoxicity of these formulations of 
NPs; such as study would be helpful to elucidate the balance among loading, release and cellular 
uptake. 
Also, these observations give some insights into the swelling behavior of environment-
responsive NPs. The matrix density had an inverse correlation with the release kinetics (or mesh 
size), and this confirms the potency of UCST-like NPs as drug carriers.
37
 An initial burst release 
of cisplatin was observed for the 21 % NPs, but not for the 34 % NPs. This implies that the initial 
burst release is a phenomenon having an inverse correlation with the matrix density. It indicates 
that a similar burst release might occur in environment-responsive NPs, and environment-
responsive NPs might release a significant amount of drugs rapidly, immediately after the 
surrounding environment changes.  
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Appendix 
Preliminary Cytotoxicity of Cisplatin-loaded NPs. 
We evaluated the cytotoxicity of the synthesized NPs so as to evaluate the feasibility of our NP 
design.  
 
Methods 
Cytotoxicity Assay of Cisplatin-loaded NPs. 
The human ovarian cancer cell line, SKOV3, was cultivated in RPMI with 
supplementation of 1 % of penicillin, streptomycin and glutamine and 10% of heat inactivated 
fetal bovine serum (HI-FBS). 2000 cells of SKOV3 cells were transferred to each well of 96-well 
plates. After 24 hours incubation, the cells settled down and NPs were added. 12 hours after the 
addition, the cell media containing the NPs were removed, rinsed twice with Dulbecco's 
Phosphate-Buffered Saline (DPBS), and added fresh 200 μL of complete RPMI. 48 hours later, 
the cell media were removed from the wells. Then 120 μL of 0.833 mg mL-1 MTT reagent in 
RPMI, without phenol red and HI-FBS, was added, and incubated for 4 hours. After the 
incubation, the media was removed from the wells, and 100 μL of dimethyl sulfoxide was added 
to the wells. 1 hour later, the absorbance at 550 nm from the wells was measured using 620 nm 
as a reference, utilizing a microplate reader (Anthos 2010, biochrom).  
 
Results 
Cytotoxicity Study of the NPs. 
We evaluated the cytotoxicity of these cisplatin-loaded NPs using SKOV3, a cisplatin 
resistant ovarian cancer cell line (Appendix Figure 2.1)
10
. The 8.4 % NPs showed the highest 
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cytotoxicity, which is consistent with their highest cisplatin release (Figure 2.1). There was no 
significant difference in the cell viability between the 31 % NPs and 48 % NPs, which agrees 
with their similar cisplatin release. We note that no toxicity due to the blank NPs was observed, 
in this range of the concentration (Appendix Figure 2.2). Also, the IC50 values of these NPs was 
higher than that of free cisplatin (Appendix Figure 2.3), due to the low percent release of 
cisplatin from NPs. Note that this result did not take the targeting ability of NPs into 
consideration; therefore, these NPs may work significantly better in vivo, significantly increasing 
the local concentration at the tumor, compared to the global concentration, and thus also the 
therapeutic index. 
  
 
Appendix Figure 2.1. Cytotoxicity Study of Cisplatin-loaded p(AAm-co-APMA) NPs. SKOV3 
cells were treated with cisplatin-loaded NPs for 12 hours followed by the extra 48 hours 
incubation after removing NPs from the cell media. The data is normalized to the viability of the 
cells that were treated with just PBS. The error bars represent the standard deviation of the mean.   
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Appendix Figure 2.2. The Cytotoxicity of blank p(AAm-co-APMA) NPs. The NP concentration 
used in this experiment was 1.2 mg mL
-1
, which is similar to the concentration of the NPs at the 
highest dose shown in Appendix Figure 2.1. The data is normalized to the population of the cells 
that were treated with PBS. The error bars represent the standard deviations of the mean.  
 
 
Appendix Figure 2.3. The Cytotoxicity of Free Cisplatin to SKOV3 ovarian cancer cell line. The 
data is normalized to the population of the cells that were treated with only PBS. The error bars 
represent the standard deviations from the mean. 
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Cytotoxicity Study of p(AAm-co-AA) NPs. 
Based on the release study, the cytotoxicity assay was performed again using SKOV3 
cells (Appendix Figure 2.4 and Appendix Figure 2.5). There was not a significant difference 
between the three types of NPs, which is against our expectation that 21 % NPs should have 
shown the highest cytotoxicity. 
This could be because SKOV3 is a cisplatin resistant cell line, and cisplatin released prior to the 
cellular uptake did not significant cytotoxicity. The 21 % NPs had the biggest difference in the 
amount of released cisplatin at the initial/very early time point, which represents cisplatin 
released prior to the cellular uptake, compared to the other two NPs. On the other hand, there 
were milder differences in the amount of released cisplatin among the three NPs for the rest of 
the time, which presumably represents cisplatin released inside the cells (Figure 2.3)  Thus, in 
the case of the 21 % NPs, a significant amount of cisplatin might be released even before 
entering the cells, and those drugs were not effective possibly due to SKOV3’s cisplatin 
resistance while cisplatin in the NPs worked better by overcoming the resistance.
10,13–16
  
Also, it should be noted that the range of cisplatin concentration we tested for p(AAm-co-AA) 
NPs was the same as that of the p(AAm-co-APMA) NPs, and no clear difference in the dose 
response is observed between these two types of NP formulations, even though p(AAm-co-AA) 
releases more cisplatin in 72 hours (about 5 times). 
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Appendix Figure 2.4. Cytotoxicity Study of Cisplatin-loaded p(AAm-co-AA) NPs. SKOV3 cells 
were treated with cisplatin-loaded NPs for 12 hours, followed by an extra 48 hours incubation 
period, after removing NPs from the cell media. The data is normalized to the viability of the 
cells that were treated with PBS. The error bars represent the standard deviation from the mean.  
 
 
Appendix Figure 2.5. The Cytotoxicity of Blank p(AAm-co-AA) NPs. The NPs concentration 
used in this experiment was 0.7 mg mL
-1
, which is similar to the concentration of NPs at the 
highest dose shown in Appendix Figure 2.4. The data is normalized to the population of the cells 
that were treated with only PBS. The error bars represent the standard deviations from the mean. 
 
 
The cytotoxicity of cisplatin-loaded p(AAm-co-AA) NPs did not show a notable 
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correlation with their matrix density.  This implies there are some factors that we might not take 
into consideration such as difference between cisplatin released outside SKOV3 cells and 
cisplatin released inside SKOV3 cells in terms of the interaction with cells, and the potential 
relationship between matrix density and cellular uptake.  
Also, the IC50 of p(AAm-co-AA) NPs was similar to that of the p(AAm-co-APMA) NPs, 
regardless of the significant difference in release profiles. The difference in the cellular uptake 
seems to explain this apparent contradiction (Figure 2.5). There is an almost 3.5 times higher 
uptake of cisplatin when p(AAm-co-APMA) NPs were used as drug carriers than when p(AAm-
co-AA) NPs were used. The significant difference in the NP cellular uptake between these two 
NP formulations could be the reason for their equal cytotoxic effect even though the p(AAm-co-
AA) NPs can release 5 times more cisplatin in 72 hours than the p(AAm-co-APMA) NPs. The 
higher release per NP appears to be compensated by a higher NP uptake. 
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Chapter 3. 
Hydrogel Nanoparticles with Thermally-controlled Drug Release. 
 
The material in this chapter has been adapted with minor modifications from the following 
publication. 
Shirakura, T.; Kelson, T.; Ray, A.; Malyarenko, A.; Kopelman, R. Hydrogel Nanoparticles with 
Thermally Controlled Drug Release. ACS Macro Letters 2014, 3, 602-606. 
 
Introduction 
 The development of hydrogel nanoparticles (NPs) that transport and deliver chemodrugs 
selectively to the tumor area is a recent strategy for improving therapeutic efficacy and avoiding 
systemic side-effects, such as renal toxicity, phlebitis, bone marrow suppression, and nausea.1,2 
Such selective delivery may be achieved by active and/or passive targeting of such NPs.3 
 Two important aspects for consideration in the development of drug delivering NPs are 
the chemodrug loading capacity and the control over its release.  An optimal design of the NPs 
would facilitate incorporation of a large amount of the drug, with efficient release to the tumor 
region, preferably in a controlled manner, while limiting release elsewhere.4 The latter is one of 
the most challenging aspects. Designing the NP matrix to enhance and enable controlled release 
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of the drug is often based on environmental stimuli,3 e.g. temperature, pH,1 light,5,6 glucose,7 
antigen,8 and reducing agents, such as glutathione.9 
 Using temperature as a stimulus to control the drug release from NPs is particularly 
attractive, because it can exploit the variation in the local temperature, typical for tumor tissues.10 
Tumor tissues have been shown to have slightly elevated temperatures, compared to the host 
basal temperature, due to an increased metabolic rate.11 Also, additional temperature differentials 
can be induced by external heating of the tumor region, e.g., by ultrasonic, magnetic field, or 
light mediated heating, targeted to the nanoparticles. 12–14 
 The integration of temperature sensitive properties into the design of hydrogel 
nanoparticles has shown promise for enhancement of the drug release to the somewhat hotter 
tumor tissues, while limiting the release elsewhere.10 Due to the flexible structures of these NPs, 
the polymer interactions inside the NPs can be made temperature sensitive, thereby altering the 
NP size and its polymer density; consequently the release efficiency of the loaded drugs changes.  
 Many different kinds of temperature-sensitive nanoparticle matrices have been 
formulated, such as poly(vinyl alcohol),15,16 cellulose derivatives,17 and complex core-shell 
polymer designs.18 Among them, one of the most common matrix systems for hydrogel NPs is 
poly(N-isopropylacrylamide) (PNIPAM), which shows good biocompatibility, as well as 
temperature-sensitivity, a so- called Lower Critical Solution Temperature (LCST) behavior in 
aqueous solution, across a biologically relevant temperature and pressure range.10,19,20 Hydrogen 
bonding is formed between the amide of PNIPAM and water, and a cage-like structure is formed 
around the isopropyl group below LCST; this solvates PNIPAM and expands the 
nanoparticles.10,21,22 On the other hand, these structures are broken above LCST; the latter 
shrinks the NPs, thereby “squeezing out” chemodrugs from the NPs, or, alternatively, tightening 
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the pores of the hydrogel, so as to reduce the chemodrug’s release.1,20–22 This matrix is often 
combined with other components, such as SiO2-coated, Fe3O4 nanoparticles, or 
butylmethacrylate, so as to enhance functionality and shift the LCST.23,24   
 
Figure 3.1.  (A) CisPt-NPs Synthesis, (B) Post-loading Procedure, and (C) Release Mechanism. 
 
 We emphasize that an Upper Critical Solution Temperature (UCST)-like behavior, 
characterized by swelling rather than de-swelling at elevated temperature, potentially lends itself 
to being very valuable as well, because swollen hydrogels do enhance the release of chemodrugs 
due to their lower polymer density.25,26 Some examples of UCST-based hydrogels are given in 
the review by Seuring and Agarwal.27  
 The combination matrix of acrylamide and acrylic acid is an example of a UCST-like 
hydrogel in the presence of a salt such as NaCl.27 This combination has been studied for both 
bulk hydrogel and NPs, since acrylic acid forms hydrogen bonds with acrylamide, bonds that 
may break at elevated temperatures, causing the hydrogel matrix to swell.25,28–30 Echeverria and 
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Mijangos have further demonstrated the ability to control the specific swelling properties of 
acrylamide-co-acrylic-acid particles by altering the crosslinker content and incorporating gold 
nanoparticles into the matrix.31 Also, acrylic acid binds a certain type of drugs tightly, due to its 
carboxyl group.1 Although these acrylamide-acrylic acid hydrogels show promising properties, 
as of yet no application of this matrix for temperature-responsive drug delivery systems has been 
reported, to the best of our knowledge, especially for cancer treatment, where the tumor is at a 
temperature slightly higher than that of the normal body temperature (37 °C).  
 Here we present NPs based on the combination of acrylic acid and acrylamide; they are 
specifically designed for temperature sensitive release of chemodrugs. We incorporated cisplatin 
into these copolymer NPs (CisPt-NPs). Cisplatin, which is a chemodrug commonly used for 
carcinoma and melanoma,2,32 was chosen as a model drug. We present the temperature sensitive 
behavior of the cisplatin release, under physiological conditions, with and without some of the 
ions that are abundantly present in vivo. We also monitored the intracellular localization of the 
NPs in cancer cells, and observed them to accumulate primarily in the lysosomes. We thus also 
investigated the temperature-sensitive release of cisplatin in a lysosome-mimicking environment. 
CisPt-NPs showed increased cytotoxicity to tumor cells with increasing temperature. The results 
presented here show that acrylamide-co-acrylic acid hydrogel NPs may be a promising candidate 
for a stable and reliable temperature-sensitive drug delivery system. 
 
Materials and Methods 
Materials 
Cisplatin was purchased from Selleck Chemical LLC. Dulbecco modified Eagle medium 
(DMEM) was purchased from Invitrogen. Fluorescein–5-thiosemicarbazide (5-FTSC) was 
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purchased from Marker Gene Technologies, Inc. All other chemicals were purchased from 
Sigma-Aldrich.  The de-ionized water used in this experiment was purified using a Milli-Q 
system from Millipore prior to the experiment.  
 
Preparation of blank p(AA-co-AAm) NPs. 
P(AA-co-AAm)  was synthesized, using the reverse micelle polymerization technique, 
modifying the method proposed by Owens1. 2.69 g dioctyl sulfosuccinate (AOT) and 1.34 g Brij 
30 were added to 38 mL of argon-purged hexane, while continuing to purge with argon. To a 
scintillation vial, 0.12 g acrylamide monomer, 0.14 g acrylic acid monomer, 0.006 g Bis-
acrylamide monomer, and 0.10 g ammonium persulfate was added. The components were 
dissolved in 1.5 mL of deionized water, and the mixture was sonicated until fully dissolved. 
While maintaining an inert atmosphere in the round bottom flask, the contents of the scintillation 
vial were added and the flask was stirred for another 20 minutes. The polymerization was 
initiated by adding 400 L Tetramethylethylenediamine (TEMED) at room temperature. After 2 
hours the reaction was quenched by opening the flask to the air for 10 minutes. Hexane was 
removed by rotary evaporation. Then, the product was washed in an Amicon stirred cell 
(Millipore) with ethanol (5x150 mL through a 300kDa MW cut-off membrane) and ddH2O (5 x 
150 mL through a 300k MW cut-off membrane). The resultant solution was filtered through a 0.2 
m pore size filter, and was lyophilized for ~72 hours. 
 
Preparation of 5-FTSC loaded NPs. 
0.207 mg of Acrylic acid N-hydroxysuccinimide ester (NSA) was mixed with 3 mg of 5-FTSC in 
50:50 mixture of 8 μL of DMF and DI water. After the overnight reaction, the mixture was mixed 
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with the monomer solution described in the section of the preparation of the blank p(AA-co-
AAm) NPs.  
 
Loading of cisplatin into blank p(AA-co-AAm) NPs. 
Cisplatin was loaded into the blank p(AA-co-AAm) NPs in a weight ratio of 1 to 5. In a typical 
loading condition, 2 mg of cisplatin was dissolved in 1 mL of deionized water. Then, 10 mg of 
blank p(AA-co-AAm) NPs were added to the solution. The solution was covered to exclude 
light, and stirred for 3 days. After that, the CisPt-NPs were rinsed with at least 7 mL of water, 7 
times, using a centrifugal filter (300 kDaMWCO) (Millipore). The concentration of the final 
solution was adjusted to be 10 mg mL-1 NP concentration in water. Inductively coupled plasma 
optical emission spectrometry (ICP-OES) (Optima 2000 DV, Perkin-Elmer) was used to 
determine the loading of cisplatin. 
 
Size and Zeta-potential Measurement. 
To measure the hydrodynamic diameter and the zeta-potential of the NPs, before and after the 
loading of cisplatin, dynamic light scattering was applied in PBS (pH 7.4) for the size analysis 
and in the deionized water for the zeta-potential measurement at room temperature using a Delsa 
Nano C (Beckman Coulter). Also, the temperature-sensitive swelling property of the CisPt-NPs 
in aqueous solution was measured using the Delsa Nano C with its temperature control function. 
In the typical experiment, 1 mL of 2 mg mL-1 NP solution was used for the measurement.  
 
Transmission Electron Microscopy (TEM) of CisPt-NPs. 
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TEM image of CisPt-NPs was taken using Philips CM100. Carbon coated grid was utilized. NP 
concentration was adjusted to 0.01 mg mL-1. No negative staining was performed. 
 
Cisplatin Release Study. 
The release of cisplatin from CisPt-NPs was evaluated either in pH 4 buffer (50 mM phthalate 
buffer with 150 mM NaCl), PBS (pH 7.4), PBS (pH 7.4) containing 1 mM MgCl2 and CaCl2, 
PBS (pH 7.4) with 10 % fetal bovine serum. A 1 mg mL-1 CisPt-NPs solution was prepared by 
suspending the CisPt-NPs in these solvents. Eighteen 1 mL aliquots of the CisPt-NPs solution 
were transferred to 1.5 mL Ependorf tubes. 6 tubes were placed into a 32 °C water bath, 6 of 
them were placed into a 37 °C water bath, and the remaining 6 were placed into a 42 °C water 
bath. At specific time points (0 hour, 6 hours, 12 hours, 24 hours, and 48 hours, for the test in 
PBS with fetal bovine serum, only 12 hours and 24 hours), one tube at each incubation 
temperature was removed and filtered, using a 100kDaMWCO centrifugal filter. Filtrates were 
collected for determination of the cisplatin released from the CisPt-NPs. ICP-OES was used to 
determine the concentration of cisplatin. 
 
Evaluation of the intracellular Behavior of p(AA-co-AAm) NPs. 
The internalization of the p(AA-co-AAm) NPs into MDA-MB-435 (MDA) cells was monitored 
by using fluorescence microscopy. The cells were incubated with the 5-FTSC labeled p(AA-co-
AAm) NPs for six hours before washing away the non-internalized p(AA-co-AAm) NPs. A 
fluorescence confocal microscope (Leica SP-5X) was used for intracellular imaging. The p(AA-
co-AAm) NPs and lysotracker were excited at 488 nm and 580 nm and the fluorescence was 
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collected between 500 nm to 550 nm and 590 nm to 620 nm, respectively. The images were 
acquired using a 60X objective in the confocal mode, with a slit width of 1 Airy unit.   
 
 
Cytotoxicity Assay of CisPt-NPs. 
The human melanoma cell line MDA cells were cultivated in DMEM containing 25 mM HEPES 
with addition of penicillin, streptomycin and glutamine (1%) and heat inactivated fetal bovine 
serum (10%).  
MDA cells were transferred to two 96-well plates with a confluency of 2000 cells per well After 
24 hour incubation the cells settled down and the drug was added. Following 12 hours 
incubation, the drugs were removed from the wells, and the cells were washed 2 times with 
DPBS before refilling them with 200 μL of complete DMEM. 48 hours later, the cell media was 
removed from the wells. Then, 120 μL of 0.833 mg mL-1 MTT reagent in DMEM, without 
phenol red, was added and further incubated for 4 hours. After four hours of incubation, the 
media with MTT reagent was removed and 100 μL of dimethyl sulfoxide was added to the wells, 
and the plate was shaken for 1 hour. The absorbances from the wells were measured using a 
microplate reader (Anthos 2010, biochrom). 
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Results and Discussion  
The CisPt-NPs were synthesized in two steps (Figure 3.1). Similar NPs have shown 
temperature-dependent swelling property near the physiological temperature.25 We have also 
confirmed that our CisPt-NPs have a temperature sensitivity by using dynamic light scattering 
(Figure 3.2), with emphasis on the lysosomal pH of 4.33 
 
 
Figure 3.2. Swelling Study of NPs. The swelling ratio is calculated by (volume at the 
temperature)/(volume at 22 °C). The error bar represents the standard error.  Temperature 
induced swelling is dramatic at pH=4. The temperature sensitivity of the size of the CisPt-NPs 
was examined in the range of 22 °C to 42 °C using dynamic light scattering. In a pH4 buffer 
(0.05 M phthalate buffer with 150 mM NaCl), Cis-NPs swelled with increasing temperature. In 
PBS (pH 7.4), Cis-NPs swell only slightly. In both cases, we observed the distribution of the size 
becoming broader as the sample is heated up, which is another sign of swelling, as reported 
previously. 
 
 The feeding ratio of acrylamide to acrylic acid was chosen to have equal Moles of the 
monomers after the polymerization.25 When the NPs are synthesized only from acrylamide or 
only from acrylic acid, the temperature sensitivity decreases.25 The emulsifier concentration and 
solvent were chosen based on Owens and our standard protocol.34,35 The combination produces 
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NPs whose size distribution is narrow, and with a size that is ideal for drug delivery application 
(i.e. avoiding rapid clearance from the body, and targeting the tumor passively in vivo).3 
 Before cisplatin loading, the size of the p(AA-co-AAm) NPs, at room temperature, was 
found to be 90 (±2) nm with polydispersity index (PDI) of 0.30 (±0.01), while after the loading 
the size was 132 (± 3) nm with PDI of  0.30 (±0.01), using dynamic light scattering (Figure 
3.3A). The images from transmission electron microscopy showed a uniform NP size distribution 
(Figure 3.3B). Both methods showed a narrow size distribution.  As expected, swelling 
drastically increases size. The zeta-potential of the p(AA-co-AAm) NPs was -57 (± 5) mV before 
the cisplatin loading, while it was -56 (±5) mV after the loading. Thus, there was significant size 
expansion with cisplatin postloading. However, there was little change in surface potential, 
indicating that the cisplatin was not just adsorbing to the surface. The loading of cisplatin was 11 
(±3) (cisplatin/CisPt-NPs) wt% of the unloaded particles.  
 
Figure 3.3(A) Typical intensity distribution of CisPt-NPs at 22 °C in PBS.  The mean size (wet) 
is 132 (± 3) nm. (B). Typical TEM Image of CisPt-NPs. TEM image of CisPt-NPs was taken to 
evaluate the size distribution of the NPs. The average size (dry) was 20.9 (± 2.5) nm. 
 
(A) (B) 
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 Acrylic acid enhances the incorporation of cisplatin by the substitution of its chlorides 
with carboxyl groups of the NPs (Figure 3.1B),1,36 What is more, the bonding of the carboxyl 
group and the platinum of cisplatin is reversible, under physiological conditions.1,36,37 In the 
presence of a high concentration of Cl-, hydronium ions, or metallic cations, the carboxyl group 
interaction with the platinum center of cisplatin gets looser (Figure 3.1C).1,29 This may also 
explain the pH enhanced release of cisplatin from the CisPt-NPs, discussed below.  
 The temperature dependent release of cisplatin was assessed in phosphate buffered saline 
(PBS) (pH 7.4), which mimics serum conditions, at three different temperatures: 32 °C, 37 °C, 
and 42 °C (Figure 3.4). The percent release of the cisplatin (η) was calculated according to the 
following equation (Eq.1). 
 
100)(/),(),( 0  TCTtCTt   (1), 
where t is the time point of the drug release study, T is the temperature of the drug release study, 
C(t,T) is the concentration of cisplatin released at that time point, and C0(T) is the initial (t=0) 
concentration of cisplatin in the CisPt-NPs. Also, the percent enhancement of the cisplatin 
release in PBS (Figure 3.4 inset) was calculated by the following equation (Eq.2). 
 
  100)(/)(),(),( 00  ttTtTt   (2), 
where η0(t) is the percent release of the cisplatin at 32 °C, at a given time point, t.  
 We monitored the cisplatin release over a period of 48 hours, starting at six hours.  Over 
the time scale we monitored, cisplatin always showed the highest release percentage at 42 C, 
compared to 37°C and 32°C. After 48 hours, 25 % of cisplatin got released from the CisPt-NPs at 
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42 °C, while only 19 % and 17 % of the cisplatin got released at 37 °C and 32 °C, respectively. 
Although the average cisplatin release is slightly higher at 37 °C, compared to 32 °C, this is not 
statistically significant.  
 The above temperature sensitivity of the drug release is attributable to three different 
factors. First, the swelling property of the CisPt-NPs decreases the density of the matrix at higher 
temperature, which could facilitate the escape of cisplatin from the matrix. Second, the reverse 
substitution reaction rate of the carboxyl group, attached to the platinum center of the cisplatin 
with chloride, is enhanced at higher temperature, because of the higher accessibility of the Cl- 
ions.1,26 Third, the rate of diffusion of the cisplatin molecules increases with temperature.  
As described above, another major factor that governs the release of the drug is the 
presence of divalent ions.29 Therefore, we evaluated the effects of such ions on the drug release 
profile, particularly those of Mg2+ and Ca2+, which are abundantly present in the blood stream, as 
shown in Figure 3.5. The concentration of each ion used is 1 mM, similar to their blood levels.38 
 The difference in the release of cisplatin becomes more evident after 6 hours. We observe 
that, over 48 hrs, 32.0 % of the cisplatin got released when the solution was at 42 °C, while only 
22.0 % and 17.8 % of cisplatin got released at 37 °C and 32 °C, respectively. 
 The increase in drug release observed in the presence of divalent ions over longer 
incubation times may be attributed to the disruption by the divalent cations of the loose 
interaction between the carboxyl groups of the NP matrix and the cisplatin molecule’s center.29 
We evaluated the release profile of CisPt-NPs in PBS with 10% fetal bovine serum, and 
confirmed the temperature-sensitivity (Figure 3.6). 
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Figure 3.4. Cisplatin Release in PBS at three different temperatures: 32 °C, 37 °C, and 42 °C. 
Error bars show the standard deviation. Inset: % Enhancement of Cisplatin Release at 37 °C and 
42 °C, compared to 32 °C. 
 
Figure 3.5. Cisplatin Release in PBS, containing 1 mM each of Ca2+ and Mg2+, at three 
different temperatures: 32 °C, 37 °C and 42 °C. Error bars show the standard deviation. Inset: % 
Enhancement of Cisplatin Release at 37 °C and 42 °C, compared to 32 °C. 
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Figure 3.6. Cisplatin Release study in PBS with 10% FBS at 37 °C and 42 °C. Error bar 
represent standard deviations. Release rises with temperature. Effect of FBS on temperature-
sensitivity was evaluated in PBS with 10% FBS. Both at 12 hour and 24 hour time points, we 
observed statistically more significant cisplatin being released at the higher temperature. 
Interestingly, the overall release was slightly lower from the test only in PBS. 
 
 
Figure 3.7. Cellular Uptake Study of 5-FTSC-loaded p(AA-co-AAm) NPs using MDA-MB-435. 
Blue indicates the nucleus, stained with Hoechst Blue. Green indicates the 5-FTSC-loaded 
p(AA-co-AAm) NPs. Red indicates the lysotracker. A significant amount of co-localization of 
red and green is observed (shown in yellow/orange). 
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 Determining the intracellular fate of the p(AA-co-AAm) NPs is essential to designing a 
drug release process, due to the importance of the local chemical environment inside the cells. 
The p(AA-co-AAm) NPs can be taken up by the cells via various intracellular pathways that 
dictate the intracellular fate of the p(AA-co-AAm) NPs. The intracellular co-localization of the 
p(AA-co-AAm) NPs was monitored using fluorescence confocal microscopy. We observe that 
these p(AA-co-AAm) NPs mostly co-localize with lysosomes, as shown in Figure 3.7. The 
overlapping of the fluorescence (seen as Yellow/Orange) from the 5-FTSC labeled NPs (green) 
with the lysotracker labeled acidic vesicles (Red) shows the co-localization. We have previously 
observed similar phenomena for the amine-functionalized hydrogel nanoparticles.35 Late 
endosomes and lysosomes are acidic in nature and have a pH value in the range of 4-5.33 Since 
we observe that most of the p(AA-co-AAm) NPs are trapped into low pH environments, we next 
studied the temperature sensitive release of drugs at acidic conditions (Figure 3.8).  
The release studies were performed by suspending the CisPt-NPs in a pH 4 buffer (50 
mM phthalate buffer containing 150 mM NaCl), which mimics the lowest pH level in the intact 
lysosome.33 
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Figure 3.8.Cisplatin Release study in pH4 buffer at three different temperatures: 32 °C, 37 °C, 
and 42 °C. Error bars represent standard deviations. Inset: % Cisplatin Release Enhancements, 
relative to Release at 32 °C. 
 
 The release of cisplatin in 48 hours at 42 °C was 75.6 %, while the release at 37 °C and 
32 °C was 54.5 % and 48.2 %, respectively. The difference in the drug release became evident 
within the first 6 hours, and remained so over the rest of the observed time period. Increasing 
amount of cisplatin was released at this low pH than in PBS and in PBS with metallic ions, 
which is consistent with what is reported previously with rhodamine 6G.39 The higher release, 
under acidic conditions, such as inside the tumor tissue as well as the lysosomes, will further 
increase the tumor selectivity of the delivered cisplatin.33,40  
 Acrylamide-co-acrylic acid hydrogel shrinks at low pH because of the protonation of the 
carboxyl groups and formation of more hydrogen bonds. 29,41 However, when the system was 
heated, these hydrogen bonds were broken, which resulted in the decrease of the matrix density 
(Figure 3.2).25 In addition, the carboxyl groups on the conjugated cisplatin were substituted by 
the hydronium ions, and cisplatin was released from the CisPt-NPs.1  
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 Also, we compared the total cisplatin release from CisPt-NPs to that from cisplatin-
loaded nanoparticles made of poly(acrylic acid-co-methyl methacrylate), which reported about 
80 % of cisplatin released in PBS at 37 °C. 42 This is a 4 times higher release of cisplatin than 
from our CisPt-NPs. However, as is shown above, more cisplatin was released from the CisPt-
NPs at the elevated temperature, at the pH of lysosomes, where we showed that CisPt-NPs were 
trapped. This selective and controlled release can further increase the therapeutic index.  
 As a proof of principle, to demonstrate the effectiveness of this technique towards in vivo 
applications, we monitored the cytotoxicity of the CisPt-NPs at two different temperatures: 37 °C 
(body temperature) and 40 °C using MDA-MB-435 (Figure 3.9). Although the cells can survive 
at temperatures greater than 40 °C, this temperature range was considered safe, avoiding protein 
denaturation. The cell viability was calculated by normalizing the signal of each condition to the 
signal from the cells treated only with PBS, at each of the two temperatures.  
 At both temperatures, a dose-dependent decline of the cell viability was observed. The 
cell viabilities, under doses of 10 μg mL-1 and 40 μg mL-1 cisplatin, were significantly lower at 
40 °C than at 37 °C, based on the unpaired two-tailed Student’s t test. Also, in general, at all 
concentrations tested, the cells treated at 40 °C showed lower cellular viability than cells treated 
at 37 °C. On the other hand, treatment with free cisplatin did not show any significant difference 
in cell viability between tests conducted at the two different temperatures (Figure 3.10). 
 Also, the cytotoxicity of free cisplatin was evaluated at two different temperatures: 37 °C 
and 40 °C. Based on the unpaired two-tailed Student’s t test, no significant difference in cell 
viability was observed. The results confirmed that the difference in the cell viability at the two 
temperatures we observed with CisPt-NPs (Figure 3.9) was due to the temperature sensitivity of 
the CisPt-NPs, and not because of the cisplatin itself. 
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Figure 3.9. Cell viability study of CisPt-NPs at two different temperatures: 37 °C and 40 °C.  * is 
p < 0.05 on the two-tailed Student’s t-test. Nanoparticle containing drug shows higher 
cytotoxicity at higher temperature. 
 
 
 
Figure 3.10. Free drug temperature sensitivity. The star (*) sign represents the cisplatin 
concentrations for which p<0.05 in the unpaired two-tailed Student’s t test. Cisplatin (free drug) 
shows unchanged or lower cytotoxicity at higher temperatures. 
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Conclusion 
In summary, temperature-sensitive NPs (CisPt-NPs), with a matrix of p(AA-co-AAm), 
were synthesized as a carrier for the chemotherapeutic drug, cisplatin, with the aim of reducing 
side effects; the latter is expected from the lowering of the release of free cisplatin in the blood 
stream and by selectively increasing its release in the tumor region, due to the temperature 
difference. We evaluated the temperature dependent release profiles of the drug from the matrix, 
as well as its in vitro cytotoxicity. With increasing temperature, these NPs showed a very 
significant increase in the release of cisplatin, in PBS, even in the absence of divalent metallic 
ions. Furthermore, adding divalent ions, which are physiologically present in the body, further 
accelerated the drug release with increasing temperature. Intracellular fluorescence imaging 
showed that most of the nanoparticles co-localize with lysosomes. The release of cisplatin 
showed an even stronger correlation with the temperature at the low lysosomal pH. Furthermore, 
we have shown that the in vitro cytotoxicity of the CisPt-NPs also increases with higher 
temperature, correlating well with the temperature enhanced drug release. We believe that the 
above results demonstrate both the feasibility and the potential utility of such temperature 
sensitive NPs as drug carriers with a high therapeutic index. 
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Chapter 4 
 
Polyethylenimine-Incorporation into Hydrogel Nanoparticles for Enhanced Chemotherapy. 
 
The material in this chapter has been adapted with minor modifications from the following 
prospective publication. 
Shirakura, T. Ray, A. Kopelman R. “Incorporating-Polyethylenimine into Hydrogel 
Nanoparticles for Enhanced Chemotherapy.” In preparation. 
 
 
Introduction 
Chemotherapy is one of the most widely used forms of cancer treatment.
 1
 It is 
noninvasive, and can be used for various types of tumors, especially those that are difficult to 
treat with surgery. However, it is also known that chemotherapy causes side effects, especially 
damaging those healthy cells that are growing rapidly, due to high systemic doses of the drug 
and its nonspecificity.
 1,2
 In order to reduce side effects, it is necessary to deliver the 
chemotherapeutic agents selectively to the tumor areas i.e., achieve a high local dose, at the 
tumor, with a low global dose. Additionally this will also reduce the systemic drug dose. 
Achieving a low therapeutic index is one of the key challenges in chemotherapy.
 3
  
Nanoparticle (NP)-based chemotherapy has been a recently used strategy to achieve 
selective delivery of these antitumor drugs. The NPs target the tumor tissue, due to their “active 
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targeting”, with surface moieties, such as antibodies, peptides and aptamers, targeting cancer 
cells,
 4–6
 and due to their intrinsic “passive targeting” property, the so-called enhanced retention 
and permeability effect.
 7
 Thus, by containing the antitumor drugs inside the biocompatible NPs, 
the selectivity of the drug delivery to the tumor is enhanced. Additionally, drugs inside the NPs 
cannot interact with other cells in the body until they are released.
 2
 By loading them inside the 
NP's, the drugs themselves can be protected from degradation by the enzymes in the plasma. 
 2,8
 
The cellular uptake is an important property of the NPs’ design. The higher the amount of 
NPs that are taken up by the cells, the more drug molecules that can be delivered, leading to 
higher cytotoxicity.
 9
 Also, a high cellular uptake is a requirement for other important properties 
of NPs, such as controlled release of drugs, and organelle-specific delivery of NPs. Controlling 
the drug release so that they can be released after the NPs are internalized is another key aspect 
of the NPs’ design. 10 Drug molecules that are released outside cells have a low probability of 
entering the cells.
 11
 Additionally, these drug molecules are subject to being pumped out from the 
cells, through the drug efflux transporters on the cellular membrane, leading to the multidrug 
resistant (MDR) effect.
 12
 However, this phenomenon can be overcome to some extent by using 
NPs as drug carriers that release drugs deep inside the cells.
 8,13
 Several strategies have been 
utilized for controlled release, such as thermally,
 10
 pH
 14
 and photochemically
 15,16
 controlled 
release systems. Also, delivery of the drug to the specific subcellular location may enhance its 
efficacy.
 17
 Drugs are mostly designed to work on a particular sub-cellular component, such as 
nucleus, mitochondria, etc., and, thus the degree of delivery to the particular organelle governs 
its efficacy. NP’s are often localized within the vesicles, such as endosomes and lysosomes, and 
various techniques have been proposed to transfer the NPs into the cytosol for even more precise 
targeting (so-called endosomal escape).
177
 In other situations, it is advantageous for the NPs to 
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avoid certain organelles, e.g., avoid the lysosomes and get to the perinuclear environment.
 18
 In 
any case, to deliver high concentrations of NPs into the cells and even closer to the site of action 
without being affected by these efflux transporters, it is important to develop nanoparticles with 
high efficiency of cellular uptake. 
One of the common strategies researchers have taken to increase the cellular uptake was 
to make the surface of these NPs positive.
 9
 Because the cellular membrane is negatively charged, 
coating with positive charged chemical groups, e.g. amines, helps NPs in binding to the surface 
of the cells; thus more positively charged NPs can be uptaken better by cells.
 19
 Also, the amine-
functionalization on the surface is important not only because of the electrostatic interactions 
between the NPs and cells, but also because the interaction with serum proteins plays an 
important role. It is reported that the cellular uptake is significantly higher in the presence of 
albumin, in case of amine-functionalized NPs, while the cellular uptake was significantly 
suppressed in case of carboxyl-functionalized NPs.
 20
 
Previously, we had developed amine-functionalized polyacrylamide based NPs for 
diagnostics and therapeutic applications, both at the in vivo and in vitro level.
 21,22
 The 
amine-functionalized PAA NPs show good cellular uptake as well as delivery of contrast agents 
and drugs. However, while the primary amine-containing acrylate monomer, N-(3-
aminopropyl)methacrylamide, which was used in those applications, increases the cellular uptake, 
its fraction in the NP formulation is limited, due to the problematic solubility of the primary 
amine-containing acrylate monomer.  
In this work, we explore a hypothesized method for improving the efficacy of the drug-
loaded hydrogel NPs by making a hybrid matrix of polyacrylamide and polyethylenimine (PEI). 
PEI is a commonly used cationic polymer that has been widely used as a DNA and RNA carrier 
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for gene therapy, especially the branched polymer with molecular weight of 25 kDa.
 23,24
 
However, the 25 kDa branched PEI itself is known to be toxic, due to its high positive charge on 
its surface, which leads to a cell-specific cause of apoptosis,  such as mitochondrial damage.
 24,25 
By incorporating PEI into PAA NPs, we expect our formulation to have 1) an increase in cellular 
uptake, due to the PEI in the NPs; 2) Increase in the therapeutic efficacy, due to the higher 
uptake; 3) a reduction in the toxicity effects of PEI in the NPs, using full/partial coverage by the 
polyacrylamide matrix.  
We additionally explore the endosomal escape ability of the synthesized PEI-
incorporated PAA NPs (PEI-PAA NPs). We hypothesize that the endosomal escape of PEI-PAA 
NPs can further enhance the efficacy of NPs, i.e., increasing the time NPs stay inside cancer cells, 
thereby overcoming NP exocytosis, while the higher cellular uptake increases the drug 
concentration in the cells. Thus, NPs’ having both higher cellular uptake and higher endosomal 
escape synergistically increases the drug efficacy. 
Our observation confirmed the above hypothesizes; we observe up-to  three-times higher 
cytotoxicity from cisplatin-loaded PEI-PAA NPs, compared to cisplatin-loaded PAA NPs 
without PEI. Also, cisplatin quantification experiments on the cells confirmed the hypothesis of a 
significantly higher cellular uptake of PEI-PAA NPs, compared to PAA NPs. However, the zeta-
potentials of the PEI-PAA NPs were lower than those of PAA NPs, against our expectation. 
Having PEI on the surface of the PEI-PAA NPs might contribute to the enhancement of the 
cellular uptake, but not just by increasing the average overall charge of the NPs. Also, the PEI-
PAA NPs did have a slight effect, of membrane disruption, on the endosomal escape, and this 
effect might contribute to the significant efficacy increase of the cisplatin-loaded PEI-PAA NPs. 
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Materials and Methods 
Materials 
Cisplatin was purchased from Selleck Chemical LLC. RPMI media was purchased from 
Invitrogen. Calcein was purchased from ICN Biomedicals Inc.All other chemicals were 
purchased from Sigma-Aldrich. The de-ionized water used in this experiment was purified prior 
to the experiment, using a Milli-Q system from Millipore. 
NPs Synthesis 
NPs were synthesized utilizing the standard protocol of polyacrylamide-based 
nanoparticles in Kopelman group.
 6
  In brief, NPs were synthesized utilizing the reverse micelle 
microemulsion polymerization.
 5
 Acrylamide, N-(3-aminopropyl)methacrylamide hydrochloride, 
3-(acryloyloxy)-2-hydroxypropyl methacrylate, and PEI were dissolved in 1.3 mL water. Then, 
the solution was mixed with 45 mL of argon-purged hexane containing 1.6 g of sodium 
dioctylsulfosuccinate, as well as Brij30. The amount of Brij30 was varied, depending on the 
formulation of NPs, so as to increase the stability of NPs: In case of PAA, 3.47 mL of Brij30 was 
added; in case of L-PEI PAA, 4.47 mL of Brij30 was added; in case of H-PEI PAA, 5.27 mL of 
Brij30 was added; and in case of 90 PEI, 5.47 mL of Brij30 was added. After 20 minutes of 
further argon-purging, 100 μL of 10 w/v% of ammonium persulfate and N,N,N′,N′-
tetramethylethylenediamine were added to the mixture, so as to initiate the polymerization. The 
reaction was complete in 2 hours. Hexane was removed by a rotary evaporator, and the 
remaining product was washed 5 times with 175 mL of ethanol and 150 mL of water, using an 
Amicon filtration system (Millipore). The NPs suspension was lyophilized, and stored at – 20 °C, 
for further investigation. 
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Loading of Alexa 647 
0.1 mg of Alexa 647 was mixed with 40 mg of PAA in 4 mL of PBS (pH 7.4) and left 
overnight. Then, the free Alexa 647 was removed from the solution by washing the NPs, using a 
centrifugal filter (100kDaMWCO,from Millipore), 7 times. For the PEI-NPs, Alexa 647-labeled 
PEI was used during the synthesis of the NPs. 
Conjugation of Triphenylphosphonium (TPP) 
TPP was conjugated to the surface of the NPs in the following method. For each 10 mg of 
NPs, 21.4 mg of EDC, and 48.0 mg of (3-carboxypropyl)triphenylphosphonium bromide (CTPB) 
were mixed in 1.5 mL PBS and 0.5 mL DMSO. The reaction mixture was stirred overnight, and 
washed with the centrifugal filter (100kDaMWCO). The final product was concentrated to 20 mg 
mL
-1
 for further investigation. 
Loading of Cisplatin 
Cisplatin was loaded in the same method as previously described.
 10
 Briefly, cisplatin was 
loaded into the NPs in the weight ratio of 1 to 5, in deionized water. Then, the NPs were washed 
with 7 mL of water 7 times, using a centrifugal filter (100 kDaMWCO). Cisplatin content was 
measured using Inductively coupled plasma optimal emission spectroscopy (ICP-OES). 
Cytotoxicity Assay 
A rat glioma cell line, 9L was cultivated in RPMI, with addition of certified heat 
inactivated fetal bovine serum (10%) and penicillin, streptomycin and glutamine (1%). The 9L 
cells were transferred to a 96-well plate with a cell population of 2000 cells per well. 100 μL of 
complete RPMI was added to each well. After 24 hour incubation, 20 μL of NP suspension in 
PBS was added to the wells, to evaluate the cytotoxicity. After 12 hours incubation, NPs in the 
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cell media were removed, and the cells were rinsed twice with 100 μL per well of Dulbecco’s 
Phosphate Buffered saline (DPBS). Then, 200 μL of complete RPMI was added, and incubated 
for another 48 hours. After the incubation, the cell media was removed from the wells, and 120 
μL of 0.833 mg mL-1 of MTT reagent in RPMI, without phenol red, was added. After 4 hours 
incubation, the media was removed and 100 μL of dimethylsulfoxide was added. 1 hour later, the 
absorbances from the wells were measured, using a microplate reader (Anthos 2010, biochrom). 
Pt Uptake Assay 
The 9L cells were cultivated in a 100 x 20 mm Petri dish. When the confluency reached 
80%, the cell media was removed, and 5 mL of fresh complete RPMI, and 700 μL of 25 μg mL-1 
cisplatin-loaded NPs were added. After 12 hours incubation, NPs that were not uptaken by the 
cells were removed, and the cells were rinsed twice with 5 mL of DPBS. The cells were 
trypsinized, and the population counted. After that, the cells were digested by soaking cells in 
70% nitric acid, for 2 days. The cisplatin contents of the cells were measured, using ICP-OES. 
F3-PEG Conjugation 
The F3 peptide and polyethylene glycol (PEG) were conjugated onto the surface of the 
NPs, following a procedure previously described. 
 26
 Briefly, 10 mg of NPs were conjugated with 
2.2 mg of F3 peptide, using 0.8 mg of Mal-PEG(2 k)-NHS as a crosslinker. All the reactions 
were performed in PBS. 
Fluorescence microscopy 
The fluorescence microscopy was performed using a Leica confocal microscope (SP-5X), 
located at the Microscopy image analysis Lab, University of Michigan. This microscope has a 
wide range of excitation source including 405nm, 455nm, and 480-600nm. The fluorescence 
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emission was detected using a CCD camera ranging and the appropriate wavelength range can be 
selected using an acousto-optic tunable filter. The pH measurements were taken with the diode 
laser at 405 nm and the white light laser at 450 nm, and the fluorescence emission was detected 
at 510nm. The lysotracker and mitotracker were irradiated at 577nm and 579nm, respectively, 
whereas the fluorescence emission was detected at 590nm and 599nm, respectively.  
Lysotracker 
  The 9L cells were plated on an glass bottom Petri dish (Mat Tek) and grown for a few 
days before incubation with NPs. The nanoparticles were incubated with the cells at 0.5 mg/mL 
final concentration for 2 hour and then washed with fresh buffer, three times, to remove any 
unbound NP. The cells with NP were further allowed to grow for 48 hours before being used for 
imaging. Then the cells were treated with a lysosomal staining probe, lysotracker red DNB-99 
for 10 minutes. The excess lysotrakcer probe was removed by washing with colorless RPMI 
media one more time.  
 
Results and Discussion 
 
 
Scheme 4.1.Synthesis Scheme of PEI NPs. 
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PEI-PAA NPs and PAA NPs were synthesized modifying a method reported previously.
 6
 
PEI was mixed with the monomers and cross-linkers prior to the polymerization. Extra volume 
of Brij30 was added during the polymerization of PEI-PAA NPs because PEI de-stabilized the 
microemulsion.  The size and the zeta-potential of synthesized NPs are summarized in Table 4.1. 
Table 4.1.PEI amount, size and ζ-potential of the synthesized NPs. PEI content describes the 
initial amount of PEI added per batch of NPs, as described in the Materials and Methods section. 
  
 
Blank 
 
with Cisplatin 
 
Blank with Cisplatin 
  
PEI 
(mg)  
size 
(nm) PDI 
  size 
(nm) PDI 
 
ζ-potential (mV) 
PAA 0 63 (±1) 0.16 (± 0.04) 
 
69 (±1) 0.25(±0.01) 
 
16.3 (± 1.1) 18.9(±1.0) 
L-PEI PAA 35.9 53(± 1) 0.25(± 0.01) 
 
87 (±1) 0.28(±0.01) 
 
12.3 (± 1.0) 8.0(±0.3) 
H-PEI PAA 54 93(± 1) 0.28(± 0.01) 
 
91 (±2) 0.25(±0.01) 
 
15.9 (± 1.3) 8.3(±0.5) 
 
 
Two types of PEI-PAA NPs were synthesized, with higher and lower PEI concentration. 
H-PEI PAA contains more PEI in the NPs than L-PEI PAA. The blank L-PEI PAA sample 
shows a similar size as the blank PAA sample. The blank H-PEI PAA samples showed 
significantly larger sizes of NPs, compared to the blank PAA and blank L-PEI PAA samples. On 
the other hand, the ζ-potential of both blank L-PEI PAA and blank H-PEI PAA samples was 
slightly lower than that of the PAA NPs, regardless of adding PEI, which was expected to make 
the NPs’ ζ-potential more positive. The lower charge could be attributed to the bigger size of the 
PEI-PAA NPs. After loading cisplatin, the size of the NPs did not change significantly except L-
PEI PAA.  
Into these NPs, cisplatin was post-loaded by the method previously described.
 10 
The 
weight % drug loadings of the NPs were calculated, using the following equation (Equation 1). 
(%)100% 


NPscisplatin
cisplatin
mm
m
loadingwt    Equation 1 
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Here, mcisplatin is the mass of cisplatin in the NPs after the loading, mNPs is the mass of NPs used 
in the synthesis. The cisplatin loading percentage is summarized in Table 4.2. There was no 
significant difference in the loading between PEI-PAA NPs and PAA NPs. Also, the amount of 
PEI in the matrix did not affect the cisplatin amount in the NPs. 
 
Table 4.2. wt % Loading of Cisplatin.  
 
Cisplatin wt % loading 
PAA 0.58 (±0.30) 
L-PEI PAA 1.2 (±0.76) 
H-PEI PAA 0.85 (±0.37) 
 
 The H-PEI PAA NPs were synthesized utilizing Alexa 647-conjugated PEI, so as to 
confirm the loading of PEI into NPs. The calculated loading of PEI was 53.9 (±7.9) μg per 1 mg 
of NPs. This confirms that almost all the PEI was successfully loaded into the NPs.  
The cytotoxicity of the NPs was evaluated without loading cisplatin (Figure 4.1). 
 
 
Figure 4.1.Cytotoxicity of Blank NPs in 9L cells (rat glioma cell line). The error bars represent 
the standard deviations. 
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The L-PEI PAA and PAANPs showed a similar degree of toxicity, while the H-PEI PAA 
showed a significantly higher cytotoxicity, especially for the NP concentrations at and above 1 
mg mL
-1
. The cytotoxicity of the H-PEI PAA indicates a possible interaction of cells with PEI, 
leading to cell death due to the cytotoxicity of PEI itself.
 24
 However, it is noted that these PEI-
loaded NPs are approximately two times less cytotoxic than free PEI (Figure 4.2). The lesser 
toxicity of PEI-PAA NPs implies coverage of PEI by PAA matrix, i.e. shielding from its 
potential toxicity. 
 
 
Figure 4.2. MTT Cell Assay for free PEI in 9L cells (rat glioma cell line). The error bars 
represent the standard deviations. As a comparison, H-PEI in Figure 4.1 is plotted. The data is 
normalized to the viability of cells treated with PBS. 
 
To understand the relationship between the amount of PEI and the properties of NPs, we 
synthesized another batch of PEI-NPs with double the amount of PEI, compared to the previous 
H-PEI PAA NPs batch. The size of the NPs increased to 112 (± 1) nm, and the zeta-potential 
dropped 12.4 (± 0.5) mV. The NPs were equally toxic to H-PEI NPs. This confirms that 
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incorporation of PEI enlarges the size of the NPs, reduces the zeta-potential, and increases the 
cytotoxicity.  
Then, we evaluated the cytotoxicity of the cisplatin-loaded NPs (Figure 4.3).  
 
Figure 4.3. MTT Assay of Cisplatin-loaded NPs in 9L cells (rat glioma cell line). Cisplatin 
concentration is shown on a logarithmic scale.  The error bars represent the standard deviations. 
The data is normalized to the viability of cells treated with PBS.  
 
 
Figure 4.4. MTT Assay of Free Cisplatin in 9L cells (rat glioma cell line). Cisplatin 
concentration is shown on a logarithmic scale.  The error bars represent the standard deviations. 
The data is normalized to the viability of cells treated with PBS. 
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IC50 values of PAA, L-PEI PAA, and H-PEI PAA were 1.85 μg mL
-1
, 0.950 μg mL-1, and 
0.60 μg mL-1, respectively. Based on Table 4.2, we need 0.86 mg/mL of PAA, 0.42 mg/mL of L-
PEI PAA, and 0.59 mg/mL of H-PEI PAA in order to achieve a 5 μg/mL cisplatin concentration, 
which is the highest concentration we tested in Figure 4.3. Blank NPs in those concentrations 
(Figure 4.1) were much less toxic (~90 % for PAA NPs and L-PEI PAA NPs and ~80 % for H-
PEI PAA NPs) than cisplatin-loaded NPs at 5 μg/mL cisplatin concentration (~ 30 % for PAA 
NPs and ~ 10% for L-PEI PAA and H-PEI PAA NPs) (Figure 4.3). In other words, the toxicity 
observed in Figure 4.3 is attributed to cisplatin. Also, when the cytotoxicity of these cisplatin-
loaded PEI-PAA NPs was compared to the cytotoxicity of free cisplatin, cisplatin-loaded PEI-
PAA NPs showed similar levels of cytotoxicity (See Figure 4.4). 
In order to elucidate the mechanism of having different levels of cytotoxicity among 
three different NPs, we evaluated the release profile of these NPs in PBS (pH 7.4) (Figure 4.5). 
 
Figure 4.5. Cisplatin Release Profile from NPs in PBS. Error bars represent the standard 
deviations from 4 trials of release study. 
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There was almost no difference in the release profile between the PAA and L-PEI PAA 
NPs. The H-PEI PAA sample released 1.4 times higher amounts of cisplatin, in 72 hours, than 
the PAA sample, but the difference is not statistically significant. Accordingly, the cisplatin 
release profile of these NPs cannot account for the difference in the cytotoxicity since they have 
similar amounts of cisplatin encapsulated. 
As Figure 4.5 shows, there is no significant difference in the release profile observed 
between three different formulations, so, in order to further analyze the cause for the high 
cytotoxicity of the L-PEI PAA and H-PEI PAA NPs, the cellular uptake of cisplatin was 
measured (Figure 4.6).  
 
 
Figure 4.6. Cellular Uptake of Cisplatin from Various NP Formulations in 9L cells (rat glioma 
cell line). The uptake signal is normalized to the cisplatin uptake when PAA NPs were utilized. 
The error bars represent the standard deviations of 3 repeating experiments. 
 
The data is normalized to the cellular uptake of PAA NPs. We observe a 6 times higher 
uptake of cisplatin when cisplatin was loaded into L-PEI PAA NPs, and a 7 times higher uptake 
of cisplatin from the H-PEI PAA. In general, more positive NPs are better uptaken by cancer 
cells.
 19
 However, our data showed that the PEI-PAA NPs can be better uptaken by cells 
85 
 
regardless of their lower zeta-potential. This implies that incorporation of PEI into the NP-matrix 
enhances the cellular uptake, not by simply changing the zeta-potential, i.e. average overall 
surface charge. 
Based on the above data, the higher cellular cisplatin concentration inside the cells with 
L-PEI PAA and H-PEI PAA NPs most probably plays a significant role in increasing the 
cytotoxicity of the cisplatin loaded L-PEI PAA and H-PEI PAA, compared to PAA NPs.  
In order to determine the distribution of the PEI encapsulated inside the NP, the release 
profile of PEI was evaluated using the H-PEI PAA NPs whose PEI were fluorescently-labeled. 
We observe that 19 % of PEI was released in 1 day, and 35 % of PEI was released in 3 days. 
This indicates that a significant fraction of the PEI was on or close to the surface. Thus, most 
probably, the free amine groups from the PEI have led to the increase in cellular uptake of the 
PEI encapsulated NP’s.  Also, this would be consistent with the higher cytotoxicity observed in 
blank H-PEI PAA (Figure 4.1) being due to the high release of PEI. 
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Figure 4.7.Release of PEI from PEI-NPs in PBS at 37°C. Error bars represent the standard 
deviations 
 
In order to confirm that the much higher cell uptake is because of the PEI on the surface 
of the NPs, the surfaces of PEI containing NPs were coated with PEG (polyethylene glycol), and 
with the nucleolin-targeting peptide, F3 (attached to the PEG). Cellular uptakes of F3-PEG 
coated, PEI containing, NPs were evaluated using these cisplatin-loaded NPs (Figure 4.8). 
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Figure 4.8. Pt uptake experiment with F3-PEG coated PEI-NPs in 9L cells (rat glioma cell line). 
The signals are normalized to the cisplatin uptake when F3-PEG coated PAA NPs were used. 
Error bars represent the standard deviations. 
 
After coating of the NP surface with F3-PEG, no significant difference in the uptake 
between PEI-PAA NPs and PAA NPs was observed (Figure 4.8). Apparently, PEI on the surface 
was successfully covered by the F3-PEG, and the coverage diminished the difference in cellular 
uptake. 
In addition to PEI enhancing the uptake of the NP’s, it can facilitate the improving of the 
efficacy of the chemo-drugs in several other ways. It is widely known that PEI has an ability to 
induce endosomal escape of nanoparticles, and this extends the time NPs stay inside the cells; 
otherwise, half of the NPs may be removed by exocytosis within 0.5 hour.
 27
 In order to test if the 
higher cytotoxicity of cisplatin-loaded L-PEI PAA and cisplatin-loaded H-PEI PAA can also be 
attributed to this ability, the NP endosomal escaping ability was evaluated. 
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We compared the transfection efficiency of L-PEI PAA and H-PEI PAA NPs with that of 
a widely accepted transfection agent, lipofectamine, using the green fluorescence protein (GFP) 
plasmid (Figure 4.9).  
 
 
Figure 4.9. GFP Transfection Experiment in 9L cells (rat glioma cell line). The scale bars 
represent 20 μm. The 9L cells were transfected with GFP plasmid, using different plasmid 
carriers.   The green color on the images shows the expression level of GFP.  Lipofectamine is a 
commercially available transfection agent. 
 
We could observe a strong GFP fluorescence from the transfected cells when 
lipofectamine was used as a transfection agent. However, the level of the fluorescence was much 
weaker when L-PEI PAA and H-PEI PAA NPs were used. However, the intracellular 
fluorescence was slightly (~20%) higher than the control, i.e. the cell incubated with the plasmid 
and PAA NP as the transfection agent.  This indicates that the PEI-NP’s may not be very 
efficient in escaping the endosomes. But the slight increase does indicate that some transfection, 
which could potentially indicate that a larger percent of drugs delivered using the PEI-NPs could 
reach the cytosol, compared to the NPs without PEI. This can also potentially play a significant 
part in increasing the drug efficacy.  
We next measured the pH of the microenvironment of the NPs so as to monitor any 
change due to the presence of PEI. The NPs are generally taken up by the cells via the process of 
endocytosis, and they are then located inside the endosomes and lysosomes.
 18
 As a result the 
average pH from of the NP microenvironment is generally observed to be slightly acidic (6.2 
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±0.2).
 28
 It has been previously shown that causing significant damage to the endosomal 
compartment can avoid staying inside the lysosome, and leads to a slight increase in the pH 
value.
 29
 However, in our case we do not observe any significant changes in the pH value of the 
NP microenvironment. This indicates that the PEI inside the NP does not cause much damage to 
the lysosomal membrane. However the membrane rupture often caused due to the proton sponge 
effect in the presence of the transfection agents does not necessarily perturb the pH.
 30
 We next 
tested the ability of the NP’s to escape the endosomes and lysosomes. This was tested in two 
different ways. We first monitor the co-localization of the nanoparticles with the acidic vesicles, 
as shown in Figure 4.10.   
 
Figure 4.10. Co-localization experiment of H-PEI PAA with lysotracker in 9L cells (rat glioma 
cell line). NPs and lysotracker are shown in green and red, respectively. A high degree of co-
localization is observed here (yellow/orange). The scale bars represent 20 μm. 
 
The cells were incubated with NPs both with and without PEI for two hours and then 
washed. Two days following internalization of the NP’s, the cells were prepared for the co-
localization experiment by staining the acidic vesicles with lysotracker. The co-localization 
between the PEI-PAA NPs and the PAA-NPs were then compared. We do not observe any 
significant difference between the levels of co-localization of these NPs with the acidic vesicles. 
The Pearson’s coefficients quantify the degree of co-localization. 31 When the value is 1, -1, or 0, 
the green and red channels are perfectly correlated, perfectly but inversely correlated, and not 
correlated, respectively.   The Pearson’s coefficients were found to be 0.88 (± 0.02) and 0.68 (± 
0.02) for PEI-PAA NPs and PAA NPs, respectively. This shows that the PEI-NP’s are not very 
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efficient in escaping the endosomes. In addition we also use PEI-NPs with TPP, which targets 
the mitochondria. This was done to deliver any NP that escapes out of the endosome to the 
mitochondria.  
 
 
Figure 4.11. Mitotracker co-localization experiment using TPP-conjugated NPs in 9L cells (rat 
glioma cell line). NPs and mitotracker are shown in green and red, respectively. Absence of 
yellow/orange color in the image shows negative co-localization of green and red. The scale bars 
represent 20 μm. 
 
Figure 4.11 shows the degree of co-localization of the PEI-NP with the mitochondria. We 
do observe some co-localization but at an extremely low level, a Pearson’s coefficient of 0.46 (± 
0.03). This observation confirms that most of the PEI-PAA are trapped inside the 
endosomal/lysosomal vesicles and only a tiny fraction are able to escape from the endosome.  
 
As a final experiment we prepared calcein loaded PEI-NPs, to check if these PEI-NPs 
cause small changes in the membrane permeability. Calcein is known to be a membrane-
impermeable dye. 
 
 
Figure 4.12. The fluorescence distribution of the calcein-loaded NPs in 9L cells (rat glioma cell 
line). Green color represents the signal from calcein. The scale bars represents 10 μm. 
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Calcein was loaded into the PEI-incorporated NPs by mixing calcein with NPs in water, 
and incubated with cells for 48 hours before imaging. The fluorescence images of the calcein 
loaded NPs are shown in Figure 4.12. Calcein leaches out of the NPs and is entrapped inside the 
vesicles as it is membrane impermeable. We observe most of the fluorescence from the 
confinements of the vesicles of endosomes/lysosomes. The fluorescence from the cytosol was 
not significantly different from the background. This shows that only a small fraction of the dye 
was able to leach out of the vesicles.  These experiments on NP co-localization and calcein 
leaching demonstrate that the damage to the membrane due to the PEI is present but not very 
significant. However, it has been shown before that transfection agents in some cases do not 
change the pH of the endosomes, or enable NP’s endosomal escape, but still do efficiently 
transfect luciferase.
 30
 The exact mechanism of transfection is still unclear and hotly debated. 
 30
 
Additionally, cisplatin molecules are extremely small and thus even minute damage to the 
endosomal membrane will be sufficient to increase its cytosolic concentration, while not 
affecting the NPs or calcein, which is a relatively larger molecule (M.W. = 666.51 Da).  
It has been reported that the PEI-cisplatin complex is more toxic than cisplatin alone, 
because of PEI’s ability of endosomal escaping. 9 Our results seem to support this claim. 
Conclusions 
(1)We successfully incorporated PEI into hydrogel PAA-NPs. (2) The PEI-incorporated 
NPs are much more cytocompatible than free PEI. (3) These PEI-PAA NPs still retain the pure 
PEI’s property of highly enhanced cellular uptake, i.e. resulting in enhancing the hydrogel NPs’ 
cellular uptake by 600% to 700%. (4) The H-PEI PAA NPs result in a higher amount of drugs 
inside the cells (5) The cisplatin loaded PEI-incorporated NPs show a much enhanced 
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cytotoxicity. (6)  The enhanced uptake of the NPs by the incorporation of PEI cannot be simply 
explained by their average surface properties (i.e., zeta-potential), and the exact mechanism of 
the phenomenon. Is it due to the surface heterogeneity? This needs further investigation. (7) PEI 
PAA NPs showed a marginal endosomal escaping ability for prolonged localization of cisplatin 
inside the cells. 
The embedding of PEI into the hydrogel matrix highly improves on the NPs’ cellular 
uptake. There may be also a marginal enhancement on the release of the cisplatin they carry, and 
the endosomal escaping ability. Overall, these factors results in an improvement on the 
cytotoxicity. 
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Chapter 5 
Summary and Future Directions 
 
5.1 Summary 
5.1.1. Chapter 1. 
Chemotherapy is one of the most common cancer treatments. However, current 
chemotherapy has problems. One of the problems is its severe side effects that are associated 
with the non-targeted distribution in the body.
1,2
 Another problem is that some of the cancer cells 
have a resistance against chemotherapy, the so-called multidrug resistance (MDR).
3
 This MDR 
ability of the cancer cells plays an important role in cancer recurrence because the origin of the 
recurrence, so-called cancer stem cells, is known to have MDR.
3
 
Nanoparticle (NP)-assisted chemotherapy may solve both problems due to their 
advantages discussed in chapter 1. NPs serve as carriers of chemotherapeutic agents, and release 
the agents in the tumor. The NPs’ targeting ability can reduce the systemic side effects.1 NPs 
have an intrinsic property to selectively accumulate in the tumor areas, by enhanced permeability 
and retention (EPR).
4
 EPR can reduce the side effects. Also, the conjugation of targeting 
moieties on the surface of NPs can further increase the targeting ability, so the side effects can be 
further reduced.
1,5
  
The NPs’ targeting ability, their longer blood circulation time, and their intrinsic MDR 
avoidance can overcome cancer MDR. Targeting ability of NPs can increase the concentration of 
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drugs in the tumor area.
1,5
 The conjugation of polyethylene glycol on the surface of NPs can 
increase the blood circulation time, and can further increase the chance of the delivery of NPs to 
the tumor areas (i.e. increase the local dose of the drugs).
6
 Due to this targeting ability and 
enhanced blood circulation time, NPs-assisted chemotherapy can deliver more drugs to the tumor 
areas than the treatment with free drugs, which can help override the cancer MDR ability. Also, 
NPs are reported to have an intrinsic ability to overcome the MDR ability as discussed in chapter 
1.
7,8
 
In addition to solving many of the current problems of chemotherapy, NPs can help in 
protecting the drugs from degradation by enzymes in the blood.
9
 
In my research, I utilized highly engineerable polyacrylamide (PAA) -based NPs. PAA 
NPs have shown their high biocompatibility both in vitro and in vivo.
5,10
 Also, various properties 
of the NPs, such as their surface charge and hydrophilicity, can be tuned by varying the type and 
the ratio of acrylamide, acrylamide-derivatives, and cross-linkers. 
I utilized cisplatin as a model drug.
11
 It is widely used for chemotherapy, but known to 
have severe side effects.
2
 In addition, the platinum atom at the center of the cisplatin molecule 
makes it easy to be quantified inside NPs as well as inside the cells. 
Utilizing this system, I assessed three critical factors of NP-assisted chemotherapy: the % 
loading of cisplatin, the release of cisplatin, and the cellular uptake of the NPs. The loading 
efficiency was discussed in chapter 2. The release efficiency was discussed in chapters 2 and 3. 
Finally cellular uptake was discussed in chapters 2 and 4. 
5.1.2. Chapter 2 
The effect of the NPs’ matrix structure on cisplatin loading and release is evaluated in 
chapter 2. I proposed a simple method of changing the matrix density, utilizing a characteristic of 
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reverse micelle polymerization. Two different formulations, p(AAm-co-APMA) NPs and 
p(AAm-co-AA) NPs, were evaluated for the effect of the matrix density upon their cisplatin-
loading ability, release profile, and cytotoxicity . No significant change in weight percent loading 
of cisplatin was observed for the NPs of different matrix density. The matrix density of both 
formulations showed an inverse relationship between the matrix density and the effective 
cisplatin diffusion coefficient (i.e. release profile), which is positively correlated with the mesh 
size of the NPs’ matrix. Also, we evaluated the cellular uptake of the amine-functionalized NPs, 
p(AAm-co-APMA) NPs, and the carboxyl-functionalized NPs, p(AAm-co-AA) NPs because this 
is another important factor to determine the therapeutic efficacy of the NPs. Amine-
functionalized NPs had significantly higher cellular uptake than carboxyl-functionalized NPs due 
to their higher interaction with cellular membrane and enhanced uptake facilitated by 
albumin.
12,13
 The release of cisplatin showed a slight correlation with its cytotoxicity. Cisplatin-
loaded p(AAm-co-APMA) NPs and cisplatin-loaded p(AAm-co-AA) NPs have similar IC50 
values, even though the p(AAm-co-AA) NPs release more cisplatin more rapidly. The similarity 
of the IC50 values can be explained by the lower cellular uptake of p(AAm-co-AA) NPs, 
compared to p(AAm-co-APMA) NPs. In principle, the tuning of the matrix density can be easily 
performed utilizing a property of the reverse micelle polymerization, and this tuning helps in 
controlling the release profile of drugs, towards optimal release. The tuned release enhances the 
delivery of drugs specifically to the targeted area, and minimizes systemic side effects.  
5.1.3. Chapter3 
Cisplatin-loaded, temperature-responsive NPs (CisPt-NPs), with a matrix consisting of 
acrylamide and acrylic acid, were synthesized so as to incorporate a trigger of cisplatin release 
and reduce its side effects. The NPs were designed to swell at the higher temperature (typical to a  
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tumor area) due to the internal temperature difference of the tumor areas and the rest of the body. 
This could also be useful for therapy with the aid of or an external heat source. The synthesized 
NPs are expected to have a reduced release of free cisplatin in the bloodstream while increasing 
the release in the tumor areas. The temperature dependence of the cisplatin release was evaluated 
in PBS, with and without divalent metallic ions. Enhancement of the release at higher 
temperature was indeed observed, and the metallic ions further accelerated the release. 
Fluorescence imaging analysis showed a high co-localization of CisPt-NPs with lysosomes, 
indicating that the NPs were at a low pH environment inside the cells. The release study at pH 4, 
mimicking  the lysosomal pH, showed a further enhancement of the temperature-responsiveness, 
as well as a boost in overall release of cisplatin. Furthermore, the in vitro cytotoxicity of the 
CisPt-NPs was shown to get accelerated at higher temperature. These results prove the feasibility 
of my temperature-responsive formulation for drug delivery applications. 
5.1.4. Chapter 4. 
Polyethylenimine (PEI) was incorporated into cisplatin-loaded PAA-NPs, and then we 
evaluated its changes with respect to cellular uptake and cytotoxicity. The PEI-PAA NPs were 
significantly more cytocompatible, compared with free PEI (25 kDa branched), but still retained 
a higher cellular uptake than the PAA-NPs, due to the presence of PEI. The PEI-PAA NPs 
showed higher cytotoxicity and higher cellular uptake, compared to PAA NPs. Coating the 
surface of the NPs with F3-PEG diminished the difference in their cellular uptake, between PEI-
PAA NPs and PAA-NPs, indicating PEI as a key factor for the enhancement of the cellular 
uptake. The enhanced uptake of NPs by the incorporation of PEI is not a simple phenomenon, 
attributable to their surface (i.e. ζ-potential) because the ξ-potential of PEI-PAA NPs were 
similar to that of the PAA NPs; further investigation is needed to understand the exact 
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mechanism. Also, marginal effect of endosomal escape of the PEI-PAA was observed. Thus, the 
higher cytotoxicity of PEI-incorporated PAA NPs than PAA NPs was the combination effect of 
significantly higher cellular uptake, enhanced release and loading, and endosomal escape.  
 
5.1.5. Overall Conclusions 
Throughout the research conducted, the following conclusions were arrived at: 
(a). Loading 
 Carboxyl-functionalized NPs can load more cisplatin than amine-functionalized NPs. 
 Loading after the synthesis of the NPs (post-loading) can achieve a higher loading than 
loading before the synthesis of the NPs (encapsulation) 
 High temperature helps in loading more cisplatin 
 The loading of cisplatin is independent of the matrix density 
(b). Release 
 While loading at high temperature can load more drugs, the percent release is lower, 
because cisplatin is trapped deeper inside the NP’s matrix. 
 The looser the matrix density, the more cisplatin is released, and the faster the release. 
 P(AAm-co-AA) can form both temperature and pH sensitive matrixes. 
Carboxyl-functionalized NPs can release more cisplatin and can do it faster than amine-
functionalized NPs 
(c). Cellular Uptake 
 Amine-functionalized NPs are uptaken more by the cells than carboxy-functionalized 
NPs. 
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 Overall surface charge (-potential) is not the only factor that controls the NPs’ cellular 
uptake. Partial charge or charge distribution on the surface may play an important role as 
well. 
Through these studies, new methods for controlling drug release from polyacrylamide-
based NPs were established: (1) tuning the matrix density (chapter 2) and (2) upper critical 
solution temperature-like behavior (chapte3). These methods enrich the options of controlling the 
drug release from hydrogel nanoparticles. Also, the enhanced cellular uptake of 
polyethylenimine-incorporated NPs, regardless of their lower ζ-potential, implies that PEI is 
enhancing the cellular uptake, not only by increasing the overall surface positivity of NPs, which 
is widely accepted,
 12
 but  also by using other mechanisms such as the introduction of surface 
heterogeneity. 
 
5.2. Future Directions 
5.2.1. In vivo Analysis. 
The analysis of NPs-assisted chemotherapy in vitro has many limitations because there is 
no blood circulation in the in vitro system. First, the passive targeting (i.e. EPR), cannot be 
evaluated using in vitro systems. Therefore, it is difficult to evaluate how effectively NPs can 
target the tumor areas. Second, the biodistribution of the NPs cannot be evaluated. Thus, no 
evaluation of systemic side effects could be made. Also, no information on the pharmacokinetics 
can be obtained. Therefore, the information on the blood circulation time of the synthesized NPs 
could not be obtained. In order to answer these questions, it is necessary to test these synthesized 
NPs in vivo. 
5.2.2. Change drugs. 
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The knowledge acquired through my projects should be applicable to other types of 
antitumor drugs as well. As a next step, different drugs should be loaded into the NPs. Some 
possible drug candidates are paclitaxel, docetaxel, disulfiram and CPA-7. Paclitaxel and 
docetaxel are drugs that are currently widely used in cancer treatment.
14,15
 As mentioned in 
chapter 1, abraxane is made of paclitaxel-loaded albumin nanoparticles, and is commercially 
available.
16,17
 However, it is difficult to chemically modify the abraxane further, because 
abraxane is composed of a protein-based carrier.
17
 Using PAA instead of albumin gives NPs 
more flexible functionalities. Disulfiram is a sulfhydryl-reacting agent, and can potentially act in 
various locations inside the cell, including the drug efflux pumps.
18
 However, disulfiram is very 
hydrophobic, and requires, for intravenous administration, an assist from a delivery system such 
as the above PAA-NPs. CPA-7 is the inhibitor of Stat3, which is also known to be highly 
expressed in cancer cells. In the appendix, it is discussed in more detail.
19
 
5.2.3. Incorporation of the Redox Sensitivity into the Nanoparticle Matrix. 
The extracellular region is known to be an oxidizing environment while the intracellular 
region is known to be a reducing environment, because of molecules such as glutathione.
20
 
Taking advantage of this environmental difference, NPs that are responsive to the redox 
environment can be synthesized. N,N’-cystamine bisacrylamide (CBA) is a cross-linker that has 
a disulfide bond in its structure. 
20,21
 Using CBA as a cross-linker of the NPs, the NPs can 
selectively degrade inside the cells. The molecular weight of the degraded polymer chain should 
be as small as possible for effective degradation.
22
 Chain transfer polymerization may be 
performed instead of our current method of free radical polymerization, due to the ability of 
chain transfer polymerization to reduce the molecular weight of polymer chains. 
22
 This type of 
NPs could be utilized for delivery of macromolecules such as proteins, DNA and RNA. 
20
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5.2.3. Endosomal escape and organelle targeting. 
One of the current problems of the hydrogel NPs discussed as a drug delivery system is 
the destination of the NPs inside the cells. They are trapped in the endosome/lysosomes. 
However, as mentioned in chapter 1, the closer drugs are released from the NPs to the site of 
action, the better the efficacy is. Therefore, it will be helpful if the NPs can escape from the 
endosomes, enter the cytosol, and eventually reaches the targeted organelle.
23
  
There are some mechanisms proposed for endosomal escape: the proton sponge effect 
and the cell membrane-fusion by liposomes.
23
 For PAA-NPs, where membrane fusion is not 
possible, the proton sponge effect is an ideal mechanism for the endosomal escape, due to its 
easiness of incorporation into PAA.  The proton sponge effect is the rapture of the endosomal 
membranes by osmotic pressure. Basic functional groups, typically amines, function as a buffer 
inside the endosomes. The buffering effect results in the recruitment of protons and Cl
-
, which 
increases the ionic strength inside the endosomes.
24
 Due to the imbalance between the inside and 
outside of the endosome, the membranes of the endosomes rapture. Typically, high amine 
containing molecules such as polyethylenimine, polylysine or endosome disrupting peptides 
containing a high amount of histidine
23
 are incorporated into the NPs.  
Combining the endosomal escape ability with organelle targeting moieties, NPs can be 
selectively delivered to the targeted organelles. Some possible organelles worth targeting are the 
mitochondria and nucleus.
23
  
104 
 
References 
1. Koo Lee, Y.; Kopelman, R. In Multifunctional Nanoparticles for Drug Delivery 
Applications; Svenson, S.; Prud’homme, R. K., Eds.; Nanostructure Science and Technology; 
Springer US: Boston, MA, 2012; pp. 225–255. 
2. Decatris, M. P.; Sundar, S.; O’Byrne, K. J. Platinum-Based Chemotherapy in Metastatic 
Breast Cancer: Current Status. Cancer Treat. Rev. 2004, 30, 53–81. 
3. Dean, M.; Fojo, T.; Bates, S. Tumour Stem Cells and Drug Resistance. Nat. Rev. Cancer 
2005, 5, 275–84. 
4. Maeda, H. The Enhanced Permeability and Retention (EPR) Effect in Tumor 
Vasculature: The Key Role of Tumor-Selective Macromolecular Drug Targeting. Advances in 
enzyme regulation 2001, 41, 189–207. 
5. Winer, I.; Wang, S.; Lee, Y.-E.; Lee, Y.-E.; Fan, W.; Gong, Y.; Burgos-Ojeda, D.; 
Spahlinger, G.; Kopelman, R.; Buckanovich, R. F3-Targeted Cisplatin-Hydrogel Nanoparticles 
as an Effective Therapeutic That Targets Both Murine and Human Ovarian Tumor Endothelial 
Cells In Vivo. Cancer Research 2010, 70, 8674–83. 
6. Wenger, Y.; Schneider, R.; Reddy, G.; Kopelman, R.; Jolliet, O.; Philbert, M. Tissue 
Distribution and Pharmacokinetics of Stable Polyacrylamide Nanoparticles Following 
Intravenous Injection in the Rat. Toxicology and applied pharmacology 2011, 251, 181–90. 
7. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in Cancer Therapy and Diagnosis. 
Adv. Drug Deliv. Rev. 2002, 54, 631–51. 
8. Cuvier, C.; Roblot-Treupel, L.; Millot, J. M.; Lizard, G.; Chevillard, S.; Manfait, M.; 
Couvreur, P.; Poupon, M. F. Doxorubicin-Loaded Nanospheres Bypass Tumor Cell Multidrug 
Resistance. Biochemical Pharmacology 1992, 44, 509–517. 
9. Yoon, H.; Lou, X.; Chen, Y.-C.; Lee, Y.-E.; Yoon, E.; Kopelman, R. 
Nanophotosensitizers Engineered to Generate a Tunable Mix of Reactive Oxygen Species, for 
Optimizing Photodynamic Therapy, Using a Microfluidic Device. Chem. Mater. 2014, 26, 1592–
1600. 
10. Shirakura, T.; Kelson, T.; Ray, A.; Malyarenko, A.; Kopelman, R. Hydrogel 
Nanoparticles with Thermally Controlled Drug Release. ACS macro letters 2014, 3, 602–606. 
11. ROSENBERG, E.; VANCAMP, L.; TROSKO, J.; MANSOUR, V. Platinum 
Compounds: A New Class of Potent Antitumour Agents. Nature 1969, 222, 385–386. 
12. He, C.; Hu, Y.; Yin, L.; Tang, C.; Yin, C. Effects of Particle Size and Surface Charge on 
Cellular Uptake and Biodistribution of Polymeric Nanoparticles. Biomaterials 2010, 31, 3657–
3666. 
13. Fleischer, C.; Payne, C. Secondary Structure of Corona Proteins Determines the Cell 
Surface Receptors Used by Nanoparticles. J. Phys. Chem. B 2014, 118, 14017 14026. 
14. Blagosklonny, M.; Fojo, T. Molecular Effects of Paclitaxel: Myths and Reality (a Critical 
Review). Int. J. Cancer 1999, 83, 151–156. 
15. Crown, J.; O’Leary, M.; Ooi, W.-S.; Crown, J.; O’Leary, M.; Ooi, W.-S. Docetaxel and 
Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience. The Oncologist 
2004, 89, 328–331. 
16. US Food and Drug Administration FDA Approves Abraxane for Late-Stage Pancreatic 
Cancer. 
17. Green, M.; Manikhas, G.; Orlov, S.; Afanasyev, B.; Makhson, A.; Bhar, P.; Hawkins, M. 
Abraxane®, a Novel Cremophor®-Free, Albumin-Bound Particle Form of Paclitaxel for the 
Treatment of Advanced Non-Small-Cell Lung Cancer. Annals of Oncology 2006, 17, 1263–1268. 
105 
 
18. Sauna, Z.; Shukla, S.; Ambudkar, S. Disulfiram, an Old Drug with New Potential 
Therapeutic Uses for Human Cancers and Fungal Infections. Molecular bioSystems 2005, 1, 
127–34. 
19. Assi, H.; Paran, C.; VanderVeen, N.; Savakus, J.; Doherty, R.; Petruzzella, E.; Hoeschele, 
J.; Appelman, H.; Raptis, L.; Mikkelsen, T.; et al. Preclinical Characterization of Signal 
Transducer and Activator of Transcription 3 Small Molecule Inhibitors for Primary and 
Metastatic Brain Cancer Therapy. The Journal of pharmacology and experimental therapeutics 
2014, 349, 458–469. 
20. Lin, C.; Zhong, Z.; Lok, M.; Jiang, X.; Hennink, W.; Feijen, J.; Engbersen, J. Novel 
Bioreducible Poly(amido Amine)s for Highly Efficient Gene Delivery. Bioconjugate chemistry 
2006, 18, 138–45. 
21. Park, K.; Lee, M.-Y.; Kim, K.; Hahn, S. Target Specific Tumor Treatment by VEGF 
siRNA Complexed with Reducible Polyethyleneimine-Hyaluronic Acid Conjugate. Biomaterials 
2010, 31, 5258–65. 
22. Gao, D.; Xu, H.; Philbert, M.; Kopelman, R. Bioeliminable Nanohydrogels for Drug 
Delivery. Nano Lett. 2008, 8, 3320–4. 
23. Biswas, S.; Torchilin, V. Nanopreparations for Organelle-Specific Delivery in Cancer. 
Advanced Drug Delivery Reviews 2013, 66, 26–41. 
24. Akinc, A.; Thomas, M.; Klibanov, A.; Langer, R. Exploring Polyethylenimine-Mediated 
DNA Transfection and the Proton Sponge Hypothesis. The journal of gene medicine 2005, 7, 
657–63. 
_ 
106 
 
 
 
 
 
 
Thesis Appendix 
CPA-7-loaded Hydrogel Nanoparticles for the Treatment of Glioma 
 
Introduction 
STAT3 is highly expressed in various types of cancer cells, such as glioma, melanoma, 
and breast cancer, and reported to play an important role for the tumor growth.
 1,2
  Inhibition of 
the STAT3 activity can reduce the cell proliferation, and cause the death of cancer cells.
 1,3
   
CPA-7, trichloronitritodiammineplatinum (IV), is a promising inhibitor of STAT3.
 1
  
Despite success in vitro and peripheral tumor models, it could not treat tumors in the brain 
because of its poor blood-brain barrier (BBB) penetration ability. 
 1
  Therefore, it is necessary for 
CPA-7 to be loaded onto a carrier that can pass through the BBB. 
Our polyacrylamide (PAA)-based NPs can pass through the BBB.  We delivered 
Coomassie blue-loaded NPs for glioma intraoperative delineation and photoacoustic imaging, 
MRI contrast agent-loaded NPs for magnetic resonance imaging (MRI) of brain tumors, and 
PHOTOFRIN-loaded NPs for the treatment of glioma.
 4–6
  Thus, CPA-7 can potentially reach 
glioma by utilizing PAA-NPs as carriers. What is more, CPA-7 has a chemical structure similar 
to cisplatin;
 1
  therefore, the knowledge and the techniques for the synthesis of cisplatin NPs can 
be applied for the CPA-7 NP formulation development. 
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Materials and Methods 
Materials. 
CPA-7 was provided from our collaborator in Eastern Michigan University. RPMI media 
was purchased from Invitrogen. All other chemicals were purchased from Sigma-Aldrich. The 
de-ionized water used in this experiment was purified prior to the experiment, using a Milli-Q 
system from Millipore. 
Synthesis of blank NPs. 
NPs were synthesized using our standard protocol. 31 % and 48% p(AAm-co-APMA), 
and 21 % and 34 % p(AAm-co-AA) from chapter 2 were synthesized for this experiment. Briefly, 
AOT and Brij30 were mixed with hexane (oil phase). There, a water phase, containing 
monomers and cross-linkers, was mixed with hexane, to form reverse micelles. Polymerization 
was initiated using APS and TEMED. After the polymerization, the hexane was removed from 
the mixture using rotor evaporation, and the surfactants and unreacted monomers were removed 
using an Amicon Stir Cell (Millipore) with 300 kDaMWCO membrane. 
Loading of CPA-7 onto NPs. 
10 mg of NPs were mixed with 0.5 mg/mL of CPA-7 in water. The mixture was kept 
overnight for the loading at room temperature, and 4 hours for the loading at 90 °C. Then, the 
solution was centrifuged at 5000 g over 5 minutes, for the removal of any insoluble materials. 
The supernatants were transferred to a 100 kDaMWCO centrifugal filter, and washed 7 times 
with 7 mL of DI water. The CPA-7 amount in the NPs was quantified using inductively coupled 
plasma optical emission spectroscopy (ICP-OES). 
Synthesis of NPs without Acrylamide-Derived Cross-Linkers. 
108 
 
The NPs were synthesized adopting the method reported in chapter 3. 2 mg of CPA-7 
was mixed with 133.2 μL of acrylic acid and 1.3 mL of water, and incubated at 90 °C for 1 hour. 
Then, 0.12 g of acrylamide and 100 mg of APS were added. This mixture was used as a water 
phase. The rest of the synthesis was the same as the synthesis of NPs in chapter 3. Briefly, the 
mixture was mixed with surfactant-containing hexane, and polymerization was initiated by 
TEMED. The product was removed from hexane by rotor evaporation, and the unreacted 
monomers and free CPA-7 were removed by 7 times washing with 175 mL ethanol, followed by 
5 times washing with 150 mL waterm, using an Amicon Stir Cell with a 100 kDaMWCO 
membrane. 
 
Results and Discussion 
Comparison of the loading at room temperature and high temperature. 
48 % poly(AAm-co-APMA) and 34 % poly(AAm-co-AA), which were synthesized in 
chapter 2, were compared for their CPA-7 loading efficiency at two different temperatures: room 
temperature and a higher temperature of 90 °C.  The NPs were mixed with free CPA-7 for 4 
hours in the case of the high temperature loading, while the NPs were mixed overnight in the 
case of the room temperature loading. The result of the loading is summarized in Table A.1. 
The loading is calculated by equation 1. 
Wt % loading = 
𝐴
𝐴+𝐵
× 100 (%)       Equation 1 
Here, A is the weight of CPA-7 in the NPs, and B is the weight of the blank NPs. 
More CPA-7 was loaded onto both types of NPs at the higher temperature than at room 
temperature. The loading at room temperature was too low for drug delivery applications. No 
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clear difference in loading was observed between p(AAm-co-APMA) and p(AAm-co-AA). 
Based on these results, the loading temperature was set to 90 °C. 
The Comparison of the CPA-7 Release from amine-functionalized NPs to that of carboxyl-
functionalized NPs. 
As a next step, the release profile was compared between p(AAm-co-APMA) and 
p(AAm-co-AA). Here, because of the expectation that a lower matrix density helps in increasing 
the release of CPA-7 (chapter 2), the matrix densities of both p(AAm-co-APMA) and p(AAm-
co-AA) were reduced (Figure A.1). More CPA-7 was released from p(AAm-co-AA) than from 
the p(AAm-co-APMA) over 7 days. Based on this result, we decided to use p(AAm-co-AA) as a 
matrix for CPA-7 delivery. 
We tested the formulations in cell lines that had a high expression of Stat3, but no notable 
effect was observed (data not shown). The result of no notable cytotoxicity might be due to the 
NPs’ low overall release of drug (Figure A.1). 
The Effect of Cross-Linkers. 
Since the formulations did not have notable cytotoxicity, the NP-matrix was further 
optimized.  In order to maximize the effective diffusion of CPA-7 inside the NPs, NPs without 
acrylamide-derived cross-linker were synthesized. Instead of acrylamide-derived cross-linker, 
CPA-7 itself was utilized as a cross-linker, as cisplatin was utilized in the previous work.
 7
  
Cisplatin can reversibly substitute its two chloride atoms with carboxyl groups, depending on the 
concentration of chloride ions in the environment.
 8
 How  CPA-7 changes its structure under 
physiological conditions is not known yet, but the chlorides in CPA-7 might behave in a similar 
way to that in cisplatin. To make CPA-7 a cross-linker, CPA-7 was mixed with acrylic acid, so 
as to facilitate the substitution of the chlorides in the CPA-7 with carboxyl groups in the acrylic 
110 
 
acid, prior to the polymerization reaction. The NPs were made from acrylamide and acrylic acid, 
roughly in a 1:1 ratio, as reported in chapter 3. The weight percent loading of CPA-7 was 0.41 %. 
The hydrodynamic light scattering based size of the NPs was 90 (±1) nm, with the polydispersity 
index of 0.25 (±0.03). The loading of CPA-7 was significantly lower than the formulations in 
which we tested the cytotoxicity, because this synthesis method reduced the ratio of CPA-7 to 
the matrix of the NPs. 
The synthesized NPs had a significantly higher overall percent release of CPA-7 (Figure 
A.2), and showed a statistically significant cytotoxicity (Figure A.3).   
In order to increase the CPA-7 loading, additional CPA-7 was loaded onto these no cross-
linker NPs at 90 °C, using the same protocol as for the loading at high temperature. This 
formulation had the highest loading of CPA-7, among all the synthesized formulations. However, 
as shown in Figure A.2, the overall release of CPA-7 (labeled as “extra loading”) was lower than 
for the no cross-linker NPs. Also, the release kinetics of these extra-good loading NPs was 
similar to that of the original no-cross-linker NPs. Thus, the extra-loading at the higher 
temperature. did not help in increasing the efficacy of the NPs. 
 
Future Directions 
The current problem of the formulation is its initial rapid release of CPA-7 from the NPs, 
as well as the low wt % loading of the NPs. Here are the possible solutions to these problems. 
Initial Rapid Release of CPA-7 
(1) The matrix needs to be tighter by adding a small amount of acrylamide-derived cross-
linkers. This should reduce the burst release. (2) No optimization of the ratio of acrylic acid and 
acrylamide has been performed. There may be a ratio -dependent difference in the release 
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behavior. Therefore, finding the optimal ratio of acrylic acid and acrylamide may solve the 
problem. (3) Albumin-PAA NPs have shown a slightly different behavior from PAA-NPs in the 
loading and release of antitumor drugs.
 9
 The investigation of the loading and release profile of 
CPA-7-loaded albumin-PAA NPs should be performed. (4) The NPs can be washed with 
Phosphate Buffer Saline (PBS) (pH 7.4) or saline solution right before the incubation with cells. 
The washing should remove CPA-7 released from the NPs due to the burst release. 
Low Loading of CPA-7 
(1) The low loading of CPA-7 is attributed to the low CPA-7 feeding during the synthesis. 
Increasing the feeding amount of CPA-7 should increase the wt % loading of CPA-7 in the NPs.   
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Table A.1. Comparison of Loading of Two Formulations at Two Different Temperatures. 
 Loading Temperature Wt% loading 
p(AAm-co-APMA) Room Temperature 0.27 % 
 90 °C  1.3 % 
p(AAm-co-AA) Room Temperature 0.17% 
 90 °C 1.4 % 
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Figure A.1. Comparison of CPA-7 Release from Two Different Formulations. 
 
 
 
 
Figure A.2. Comparison of CPA-7 Release from no cross-linker NPs and Extra loading NPs. 
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Figure A.3. MTT Assay of no cross-linker NPs using GL26 cells. 2.5 days Incubation with cells. 
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